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Abstract 
Pluripotent stem cells (PSC) are a tantalizing prospect for a renewable source of 
patient-specific hematopoietic stem cells (HSC), however efforts to obtain PSC 
derived HSC capable of long-term engraftment have largely failed.  We set out 
with the primary aim of identifying novel molecular signatures of definitive 
hematopoiesis, so that these signatures could be applied to improve generation 
and isolation of HSC in vitro. Toward this end we pursued both discovery and 
application based strategies centered on Runx1; a transcription factor that is 
critical for the development of definitive HSC.   
The discovery arm identified epigenetic modifications at Runx1 cis-regulatory 
elements that temporally associate with the transition from primitive to definitive 
hematopoiesis in vivo. We replicated these signatures in vitro by overexpressing 
HOXB4 in hematopoietic progenitors derived from murine embryonic stem cells 
(ESC), and found that HOXB4 directly interacts with the definitive-specific distal 
Runx1 promoter and mediates increased transcription, loss of DNA methylation, 
and acquisition of active histone modifications at this locus.  
We next applied our understanding of Runx1 regulation to generate a panel of 
clonal mESC lines harboring targeted, single-copy fluorescent reporters under 
the transcriptional control of Runx1 cis-regulatory elements.  These lines were 
used to interrogate the hematopoietic activity of each element independent of 
copy number and chromosomal position, allowing us to identify combinations that 
provided optimal activity and fidelity.  Building upon this, we established mESC 
lines harboring synthetic fluorescent and bioluminescent mini genes replicating 
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the structure of the endogenous Runx1 locus and demonstrated that these lines 
reflect the dynamic promoter switching that occurs at Runx1 during 
hematogenesis.  Sub-fractionation of embryoid body cells based on promoter 
activity revealed that nearly all colony forming cells (CFC) reside in the distal 
promoter expressing fraction. With this information we identified specific 
conditions that could further mature and expand distal positive cells.   
Collectively, this work identified a previously undescribed molecular signature of 
definitive hematopoiesis and the mechanism by which it is established. In 
addition, we applied this knowledge to generate tools with which to interrogate 
hematopoietic development in vitro, and have demonstrated their utility in 
optimizing strategies for obtaining definitive hematopoietic progenitors from PSC.   
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HSC Transplant, Limitations, and the Promise of PSC 
Stem cell based therapies offer new and exciting possibilities for 
regenerative medicine. While often considered cutting edge or futuristic, stem 
cells have been used clinically to treat human disease for nearly a half-century in 
the form of bone-marrow transplant. The end of World War II ushered in a new 
era of medical research and prompted efforts which ultimately lead to seminal 
discoveries into the biology of marrow transplantation; namely that transplanted 
marrow is capable of rescuing recipients from lethality associated with acute 
exposure to ionizing radiation1. Shortly thereafter,  the radioprotective effect of 
marrow was found to come from its ability to establish life-long donor-derived 
hematopoiesis in the recipient2,3; a phenomenon later found to manifest via the 
presence of rare hematopoietic stem cells (HSC) within the transplanted marrow; 
each capable of generating all mature lineages of the hematopoietic system, 
while simultaneously retaining the ability to self-renew over the life-span of the 
organism4-6. The reconstituting ability of HSCs is now exploited clinically to treat 
a multitude of human diseases including hematopoietic malignancies such as 
leukemia, lymphoma, and myeloma; as well as inborn errors of metabolism, and 
more recently in the correction of genetic skin disorders and even HIV7-9.   
Significant advancements have been made in the practice of HSC 
transplant, yet the procedure remains challenging, with morbidity and mortality 
occurring in a significant portion of recipients, predominantly due to complications 
associated with immunological mismatch, stemming from a lack of suitable HLA 
matched donors 7. Additionally, insufficient HSC content within the graft can 
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result in graft failure; a problem that stems largely from the extreme rarity of HSC 
and a lack of effective methods for their expansion ex vivo10.  Umbilical cord-
blood has emerged as a promising new source of HSC, but is not without many 
of the complications associated with transplant of marrow derived HSC11.  
Substantial efforts to expand/and or maintain HSC ex vivo have been met with 
limited success, though recent high-throughput screens have identified small 
molecules capable of expanding and/or maintaining HSC ex vivo 12,13.  Though 
the long-term effects of these molecules remain under investigation, they have 
nonetheless shown enough promise to warrant clinical investigation in humans.  
In light of these limitations, there remains a pressing need for novel sources of 
HSC for transplantation.  
Pluripotent stem cells (PSC) such as embryonic stem cells (ESC) and the 
more recently derived induced pluripotent stem cells (iPSC) offer exciting 
prospects for renewable and patient-specific sources of in vitro derived HSC14-19. 
PSC are characterized by their ability to self-renew in culture while maintaining 
pluripotency, and in the case of iPSC, can be derived from a specific individual; 
thus circumventing complications associated with immunological mismatch.  
Shortly after their isolation, human PSC were shown to possess the capacity to 
undergo hematopoietic differentiation in vitro20. In spite of the successful 
derivation of many mature hematopoietic lineages from PSC, efforts to generate 
HSC capable of long-term engraftment have largely stagnated.  
A significant obstacle to the derivation of engraftable HSC from PSC is the 
fact that PSC hematopoietic specification is biased toward a transient, early 
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embryonic phase of blood generation that is referred to as primitive 
hematopoiesis21,22.  Primitive hematopoiesis predominantly generates cell types 
that serve the purpose of oxygen supply and tissue remodeling within the 
embryo, but do not contribute to the HSC pool that sustains life-long 
hematopoiesis after birth. The so called definitive phase of hematopoiesis occurs 
later in development and is the predominant source of HSC that are responsible 
for life-long reconstitution of adult hematopoiesis. It is definitive HSC that 
possess the unique capacity to provide long-term hematopoietic reconstitution 
posttransplant. Thus, the major hurdle to the realization of PSC derived HSCs is 
our present inability to specify and efficiently isolate definitive HSC during in vitro 
differentiation of PSC.  
Hematopoietic ontogeny 
The mammalian hematopoietic system is tasked with replenishing millions 
of mature blood cells in a tightly controlled manner on a daily basis. Maintaining 
this output over the course of a lifetime is accomplished by a small population of 
HSC residing in the bone marrow. Substantial progress has been made in 
defining the adult hematopoietic hierarchy and the intrinsic and extrinsic signals 
that direct the formation of each committed lineage from HSC, however the 
developmental processes that lead up to the emergence of HSC in the embryo 
are less clear.   
Early studies of vertebrate development in chick embryos identified the 
extra-embryonic yolk sac (YS) as the first site of blood formation 23. The 
observation that YS blood formation occurs in a spatiotemporally similar manner 
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as the YS vasculature prompted speculation that primitive blood and endothelial 
cells arise from a bipotential mesodermal precursor, termed a ‘hemangioblast’ 24. 
It was not until much later that direct evidence for the presence of a mammalian 
hemangioblast (HB) was suggested during in vitro differentiation of mouse 
embryonic stem cells (mESC) 25,26. Confirmation of an in vivo hemangioblast 
came via the use transgenic mice expressing green fluorescent protein (GFP) 
from the murine brachyury  locus27.  Here, it was observed that at day 7.0-7.5 a 
subset of mesodermal cells located within the posterior region of the primitive 
streak begin to express brachyury and the vascular endothelial growth factor 
receptor Flk1 (VEGFR-2), and when placed in supportive culture conditions are 
able to give rise to both adherent endothelial and non-adherent hematopoietic 
progeny at a clonal level. These cells were dubbed blast-colony forming cells 
(BL-CFC) 28. In the embryo, a subset of the brachyury expressing mesodermal 
cells eventually migrate to the YS, where they produce the endothelial and 
primitive hematopoietic cells that make up characteristic blood islands29,30. At this 
time, the prevailing wisdom held that mesoderm derived HB located in the YS 
produced the HSC of the adult hematopoietic system29,31-33.  
The theory of a YS origin for adult vertebrate HSC was questioned early 
on by results from quail-chick grafting experiments, whereby the cells (and thus 
cellular progeny) of each species can be distinguished by the appearance of the 
nuclei. In these experiments, two-day old (pre-vascularization) quail embryos 
were grafted onto chick YS and allowed to progress through hematopoietic 
development 34. Upon examination of peripheral hematopoietic organs, all mature 
6 
 
blood types were derived from quail; suggesting that the origin of adult definitive 
HSC resides within the embryo proper, and not the YS. Analogous experiments 
using amphibian embryos reached a similar conclusion35.  The theory of an 
embryonic origin of HSC would remain controversial until the findings were 
corroborated by rigorous transplantation experiments in mice. In these studies, 
systemic transplantation of embryonic tissues from E8-12 identified that the first 
HSC capable of long-term, multilineage reconstitution of adult hematopoiesis 
arise not in the yolk sac, but autonomously within the aorta-gonad-mesonephros 
(AGM), vitelline, and umbilical arteries of E10.5 embryos 36-38. Around E12 HSC 
activity can be detected within other anatomical regions, including the YS and 
fetal liver, but because this follows the onset of circulation, it cannot be ruled out 
that these regions are seeded by HSC or pre-HSC emanating from the AGM. As 
the HSC numbers present in the E12 fetal liver exceed that which can be 
produced in the AGM alone, an additive contribution of HSC from YS, placenta, 
or other anatomical regions cannot be completely dismissed; whether through de 
novo generation or via the maturation of HSC precursors generated elsewhere 39.  
Nonetheless, the AGM is widely considered the primary site of HSC generation 
within the embryo. Once formed, nascent HSC enter the circulation and colonize 
the fetal liver where they undergo significant expansion prior to a final transition 
to bone marrow39.   
One of the important observations made in early studies was the close 
proximity of nascent hematopoietic cells and vasculature; specifically vascular 
endothelium lining the floor of the dorsal aorta and umbilical and vitelline 
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arteries40,41.  Lineage tracing experiments in transgenic mice expressing Cre 
recombinase under the control of the vascular endothelium  restricted VE-
cadherin regulatory elements supported the endothelial origin of AGM derived 
HSC42. This process would later be directly observed in a series of elegant time-
lapse microscopy experiments. Eilken et al utilized in vitro differentiation of 
mESC engineered to express fluorescent reporters under control of VE-cadherin 
regulatory elements. In these experiments mesodermal precursors isolated 
based on Flk1 expression were placed in culture and observed as they 
underwent hematogenesis. Time-lapse videos clearly demonstrated the 
formation of VE-Cadherin+ endothelial clusters that began to bud non-adherent  
CD41 and CD45+ hematopoietic cells43. Similar time-lapse observations of this 
process in zebrafish and in aortic explants from mouse embryos would set forth 
the model in which HSC form via a novel endothelial-to-hematopoietic transition 
(EHT)44,45.   Further dissection of this process brought forth a model where a 
bipotential HB is not the direct precursor of embryonic hematopoietic cells but 
rather that an intermediate, hemogenic endothelium (HE) is formed which then 
directly produces non-adherent, definitive hematopoietic cells within the embryo 
43,46.  Utilizing a novel ex vivo stromal co-aggregation strategy and systematic 
transplantation analyses of fluorescence activated cell sorting (FACS) purified 
cell populations, Rybostov et al. refined the phenotypic hierarchy of 
hematogenesis within the AGM region.  In these studies, VE-cadherin+CD45-
CD41+ type I pre-HSC residing within the wall of the aorta transition to VE-
cadherin+CD45+CD41+  type II pre-HSC before ultimately becoming mature 
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HSC as defined by their ability to engraft without the need for an ex vivo  
maturation step47.  
  Germ layer interactions between mesoderm and endoderm are necessary 
for embryonic hematogenesis 48-51.  Specifically, the activity of VEGF, bFGF, and 
TGF-β1 have been identified as endodermal signals important for specifying 
hematopoiesis from mesodermal progenitors52.  Hedgehog signaling is important 
for the formation of definitive hematopoiesis in zebrafish, and for the formation of 
hematopoietic cells during in vitro differentiation of ESC, possibly due to its role 
in the formation of aortic vasculature53-55.  Indeed, Hedgehog signaling lies 
upstream of the VEGF and Notch signaling pathways; both of which are crucial to 
the formation of HSC from aortic endothelium54,56.  In addition, both Wnt and 
BMP4 signaling are important to the formation of blood within the embryo, in part 
due to their effects on mesodermal patterning57-59. 
The activities of these signaling pathways are integrated into a complex 
network of interacting transcription factors 60,61.   Apical blood regulators including 
Cdx4 and Hox members initiate transcriptional programs required for the 
specification of blood62,63. Notable downstream transcription factors include: 
Gata2 64, Scl 65,66, Lmo2, 67,68, Fli169, and the runt-related transcription factor-1 
(Runx1) 70,71; all of which are required for definitive hematopoiesis 69,72.  In vivo 
studies using knockout mESC lines by Lancrin et al. placed the temporal 
requirement for SCL at the transition from hemangioblast to hemogenic 
endothelium, and confirmed the observations of others that Runx1 is required for 
the transition from hemogenic endothelium to definitive hematopoiesis73. As the 
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phenotypic characterization of hemogenic endothelium has been refined, 
regulators of its formation have been identified. Iacovino et al. identified HoxA3 
as an apical regulator of hemogenic endothelium; essentially functioning as a 
molecular gatekeeper to the initiation of hematopoiesis by activating a large 
cohort of endothelial specific genes while simultaneously repressing 
hematopoietic specific genes including Runx174. The transcription factor Sox17 
has recently been found to play a role in the generation and expansion of 
hemogenic endothelium via modulation of the Notch pathway75.  Complex 
regulatory circuits have been identified between many of these transcription 
factors, underscoring that hematogenesis is a dynamic, multifaceted interplay 
that must be intricately regulated 76.   
The information gleaned from these studies has provided valuable insight 
into the basic biology of blood development, and continues to pave the way for 
applied efforts to obtain transplantable HSC from PSC.  
Hematopoietic Differentiation of PSC 
 PSC have demonstrated their utility as a tool for the interrogation of 
developmental processes leading to the formation of blood; allowing both easy 
access and observation of intermediate stages of development and, particularly 
in the case of mESC, their amenability to genetic modification .  
 Spontaneous differentiation of mESC in vitro provided the first evidence of 
their capacity to undergo hematopoietic differentiation77. When removed from 
conditions promoting pluripotency, mESC generate complex three dimensional 
embryoid bodies (EB) containing cell types derived from multiple germ layers. 
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Characteristic blood islands with similar appearance and cellular composition to 
that of YS can be observed within these structures. Methylcellulose based 
colony-forming unit (CFU) assays over the time-course of EB formation 
demonstrated that hematogenesis occurs in a sequence similar to that in vivo, 
with primitive erythroid cells (EryP) appearing first at day 6, followed by more 
definitive cell types of the erythroid lineage (EryD) and macrophages at later 
time-points78.  Although the embryonic to adult globin switch occurs within EBs, 
the inability to produce other adult definitive lineages, namely lymphoid cells and 
CFU-Spleen, suggests that in vitro ESC differentiation is biased toward the 
primitive type hematopoiesis observed in the yolk-sac79,80.  As expected based 
on these observations, EB derived hematopoietic progenitors have not been 
demonstrated to have the capacity to significantly repopulate adult 
hematopoiesis after transplantation, although a few studies have observed trace 
levels of chimerism in immune deficient mouse strains when transplanting cells 
from late stage EBs81,82.  
 These limitations prompted the development of new differentiation 
strategies aimed at promoting definitive hematopoiesis and, ultimately, 
engraftable HSC. One of the first broad modifications was the co-culture of ESC 
with hematopoietic-supportive stromal cells. The OP9 stromal line derived from 
the calvaria of M-CSF deficient mouse embryos was one of the first to 
demonstrate reproducible induction of multi-lineage hematopoiesis from ESC, 
including low levels of lymphoid cells, albeit restricted to B and NK cell 
lineages83.  Considering the fact that lymphoid capacity is a trait thought to be 
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relegated to adult-type definitive hematopoietic progenitors, the fact that 
progenitors obtained from OP9 co-cultures fail to engraft suggests that the 
current definitions of primitive and definitive hematopoiesis may require 
refinement, or that additional maturation steps may be required to obtain HSCs 
capable of homing to, and/or thriving within the adult marrow microenvironment.  
The latter explanation is particularly interesting in light of the fact that YS derived 
progenitors from E 9.0 embryos are able to generate long-term reconstitution 
when transferred directly into the liver of newborn recipients84.   
Attempts to overcome this hurdle via the enforced expression of cell 
intrinsic regulators have shown mixed success. Retroviral transduction of day 5 
EB cells with the Bcr/Abl oncogene followed by in vitro expansion and 
transplantation produced multi-lineage hematopoietic chimerism, but perhaps not 
surprisingly, ultimately resulted in leukemia85.  A recent report documented the 
ability of a short isoform of Runx1, Runx1a, to promote both the formation and 
short-term engraftment capacity of hESC derived hematopoietic progenitors, 
however questions have been raised as to whether this was the result of 
oncogenic transformation86. Perhaps the most successful example of cell intrinsic 
modulation of HSC development from PSC has come via the overexpression of 
the definitive HSC specific homeotic regulator, HoxB4.  By merging HoxB4 
overexpression and OP9 co-culture, Kyba et al. were able to demonstrate the 
generation of hematopoietic cells capable of leukemia-free, long-term multi-
lineage engraftment from both ESC and YS87. This latter discovery strengthens 
the argument that cell intrinsic regulatory pathways can be effectively modulated 
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in such a way as to confer “definitiveness” unto formerly primitive hematopoietic 
cells. In addition to its utility for interrogating the molecular profile of definitive 
hematopoiesis, HoxB4 has allowed proof of concept experiments for gene 
correction of PSC followed by hematopoietic differentiation, transplant, and 
subsequent therapeutic correction of disease88,89.  
Unfortunately, one of the most consistent themes across the many 
systems for hematopoietic differentiation is a lack of reproducibility. This has less 
to do with the merit of the individual studies as it does the inherent variability 
introduced by undefined culture conditions; whether via the supplementation of 
culture media with fetal calf serum or through the use of stromal cell lines for co-
culture or the generation of conditioned media. To avoid this problem, many 
groups have opted to explore fully defined culture systems based off the insights 
gleaned from basic research into the development of HSC in vivo. The first step 
along the path from pluripotency to blood is the transition to an epiblast stage; a 
process can be accomplished simply by removing PSC from the conditions that 
maintain pluripotency 90. The second step of specifying mesoderm from the 
epiblast stage is promoted by the addition of BMP4 91,92.  Additional factors are 
required for the formation of hemangioblast from mesoderm, as evidenced by the 
lack of BL-CFC in cultures supplemented with BMP4 alone. The addition of 
appropriate levels of VEGF is sufficient for low levels of BL-CFC activity; however 
the combination of VEGF, bFGF, and Activin A dramatically enhances the 
formation of HB 91. Final specification to the hematopoietic lineage is promoted 
by a wide array of hematopoietic cytokines, including stem-cell factor (SCF), 
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thrombopoietin (TPO), FMS-like tyrosine kinase ligand (Flt3), interleukin-3 (IL-3), 
and interleukin-6 (IL-6) 87,93.    
Collectively, these findings have provided a platform from which to build in 
the ongoing effort to identify conditions that promote the final transition to 
definitive HSC. Undoubtedly, these efforts will be fostered by the identification of 
new phenotypic and molecular signatures of definitive HSC.  
The Role of Runx1 in Definitive Hematopoiesis 
 The Runt-related transcription factor, Runx1 (also known as AML1 and 
Pebp2α), and its shared binding partner CBFβ are part of the evolutionarily 
conserved core-binding factor (CBF) family of transcriptional regulators. 
Members of this family are distinguished by a 128 amino acid region of homology 
to the Drosophila pair-rule gene runt.  This evolutionarily conserved ‘runt domain’ 
functions to specify Runx1 binding to its target DNA sequence, YGYGGT, and to 
mediate the interaction with its β-subunit, CBFβ.  
 In mouse and (man), three Runx genes have been identified; Runx1 
(AML1), Runx2 (AML3), and Runx3 (AML2); with each performing different tasks 
during embryonic development.  In humans, RUNX1 and CBFβ are frequently 
sites of oncogenic translocations in acute myeloid leukemia (AML) and acute 
lymphoid lymphoma (ALL), underscoring an important hematopoietic role for 
Runx194.   In the embryo, Runx1 is notable for its important role in the formation 
of definitive HSC during development as evidenced by the fact that Runx1 
knockout embryos die by E12.5, exhibiting a complete lack of definitive 
hematopoiesis 95.  Interestingly, the loss of Runx1 appears to preferentially 
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impact intra-embryonic definitive, but not the earlier primitive waves of 
hematopoietic development. Subsequent studies have specified its requirement 
to the transition from HE to definitive HSC96.  The precise role of Runx1 in the 
transition from HE is currently under investigation. Genome-wide analysis of 
changes to the epigenetic landscape mediated by Runx1 during this transition 
identified global rearrangements in the binding profiles of master hematopoietic 
regulators SCL, Fli1, and C/EBPβ97.  These rearrangements were associated 
with the modulation of pathways associated with hematopoiesis and cell 
morphology. Thus Runx1 expression in HE is responsible for global induction of 
hematopoietic cell fate, underscoring its role as a master regulator of the 
hematopoietic program.  
Organization and Transcriptional Regulation of Runx1 
 The murine Runx1 locus covers roughly 220kb on chromosome 16, and 
contains 7 alternately spliced exons; allowing for the generation of an assortment 
of alternately spliced isoforms. Transcription initiates from two spatially distant, 
alternative promoters; the Proximal (P2) promoter is located just upstream of the 
second exon, while the Distal (P1) promoter is located ~100kb upstream from P2. 
The two promoters are separated by the first exon and an unusually large 
(~100kb) intron. Located ~23kb downstream form the P1 promoter, and within 
the first intron, is an enhancer element that confers hematopoietic specificity to 
the two Runx1 promoters via its interaction with Gata2, Ets factors, and the 
SCL/Lmo2/Ldb1 complex98,99. When isolated in plasmid-based reporter assays 
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and transgenic mice, neither promoter appears to direct hematopoietic specific 
transcription 100. 
 The Runx1 locus is particularly interesting in that the P1 and P2 promoters 
are differentially active during hematopoietic development 101. Specifically, P1 
activity dominates only in definitive hematopoietic stem and progenitor cells of 
the FL and adult102,103. Structural differences have been noted between the two 
promoters, with the proximal promoter being described as resembling that of 
“housekeeping” gene promoters in that it contains binding sites for more generic 
transcriptional regulators and few sites associated with lineage-specific 
transcription factors 100.  On the other hand, the P1 promoter is more complex in 
terms of transcription factor binding sites, with experimentally validated binding 
sites for lineage-specific transcription factors, including Gata and Runx1, pointing 
to its potential autoregulation101,104. The mechanism of translation also differs 
between the two promoters, with P1 translation occurring via a cap-dependent 
mechanism, while P2 translation occurs via a cap-independent IRES-mediated 
process 105. The P1-Runx1 isoform (Runx1c) differs from the P2-Runx1 isoform 
(Runx1b) in its 5’ UTR, and by the inclusion of unique amino acids at its N 
terminus. The biological roles of these isoforms are currently under investigation, 
though several studies have noted differences in DNA-binding affinity, and the 
ability of each isoform to promote cellular proliferation and differentiation106,107.  
 The striking temporal association of the Runx1 promoter switch with the 
formation of definitive HSC provides a unique signature with which to further 
dissect the molecular and phenotypic profiles of primitive and definitive 
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hematopoiesis. In doing so, it will become possible to more readily identify 
conditions that bias PSC differentiation toward definitive hematopoiesis, and 
ultimately HSC.  
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Chapter 2.  
DNA methylation of Runx1 regulatory regions correlates with transition 
from primitive to definitive hematopoiesis in vitro and in vivo. 
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Foreward 
The transcription factor Runx1 (AML1) is a central regulator of hematopoiesis 
and is required for the formation of definitive hematopoietic stem cells (HSC). 
Runx1 is alternatively expressed from two promoters: the proximal (P2) prevails 
during primitive hematopoiesis, while the distal (P1) dominates in definitive HSC. 
While some transcription factor binding sites and cis-regulatory elements have 
been identified, a mechanistic explanation for the alternative promoter usage 
remains elusive. We investigated DNA methylation of known Runx1 cis-elements 
at stages of hematopoietic development in vivo, and during differentiation of 
murine embryonic stem cells (ESC) in vitro. We find at the P1 promoter, loss of 
methylation correlated with the primitive to definitive transition in vivo. In vitro, 
hypomethylation, acquisition of active chromatin modifications, and increased 
transcriptional activity at P1 are promoted by direct interaction with HoxB4, a 
transcription factor that confers definitive repopulation status on primitive 
hematopoietic progenitors. These data demonstrate a novel role for DNA 
methylation in the alternative promoter usage at the Runx1 locus, and identify 
HoxB4 as a direct activator of the P1 promoter. This epigenetic signature should 
serve as a novel biomarker of HSC potential in vivo, and during ESC 
differentiation in vitro. 
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Introduction 
Understanding the molecular pathways governing the development of 
mammalian hematopoietic stem cells is crucial to identifying methods for their 
derivation from pluripotent cell sources. Of the key players involved in the 
formation of HSC, the runt-related transcription factor, Runx1, plays an essential 
role. Without Runx1, hemogenic endothelium of the aorta-gonad-mesonephros 
(AGM) does not undergo hematopoietic transition and Runx1 knockout embryos 
fail to survive past 12.5 days gestation with a complete loss of definitive 
hematopoiesis95,96,108,109. This defect is mirrored during hematopoietic 
differentiation of embryonic stem (ES) cells in vitro, underscoring the role of 
Runx1 as a fundamental regulator of the hematopoietic program during 
development73,110.  
Runx1 serves as the α-subunit of the core binding factor complex and is 
the most common translocation in acute myeloid leukemia in humans94,111. 
Defining regulation of the Runx1 locus is necessary to understand the complex 
functional roles and tightly regulated activity of Runx1 during HSC development 
and hematopoietic malignancy. Runx1 transcription is controlled by two 
developmentally regulated alternative promoters and an intronic enhancer (+23) 
element98-101. Intriguingly, promoter usage follows a pattern whereby the proximal 
(P2) promoter initiates early in primitive hematopoiesis, while distal (P1) promoter 
driven transcription appears later in definitive hematopoietic cells103,112. Strikingly, 
distal promoter predominance is temporally associated with peak HSC expansion 
in the fetal liver and continues into adult marrow where purified HSC utilize the 
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distal promoter almost exclusively101,103,106,113. While Runx1 core promoter 
elements fail to restrict reporter expression to the hematopoietic lineage, the 
intronic +23 enhancer is sufficient to drive hematopoietic specificity via interaction 
with Gata2, Ets factors, and the SCL/Lmo2/Ldb1 complex99,100. While much has 
been learned about Runx1 promoter and enhancer usage, the precise 
mechanisms responsible for the observed promoter switch are not understood.  
 DNA methylation is an epigenetic regulatory mechanism that contributes 
prominently to embryonic development and lineage commitment in the 
hematopoietic system114-116. Recent advances in genome-wide analysis of 
methylation have identified tissue specific differentially methylated regions 
(TDMR) as dynamic regulators of gene expression during development and 
disease117. Further evidence suggests that intronic enhancers are frequently 
TDMR involved in lineage commitment and can influence the usage of alternative 
promoters117,118. In spite of these observations, methylation of the Runx1 
regulatory elements has not yet been assessed in the context of hematopoietic 
development, and relatively little is known about the mechanisms underlying the 
Runx1 promoter switch. 
 Here, we examine the DNA methylation status of Runx1 regulatory 
elements at stages of hematopoietic development in vivo and during 
hematopoietic differentiation of ESC in vitro. We find the proximal (P2) promoter 
is unmethylated in all cell types examined including pluripotent murine embryonic 
stem cells (mESC). In accordance with its role as a hematopoietic specific 
enhancer, a striking loss of methylation is observed at the +23 enhancer element 
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upon commitment to the hematopoietic lineage in vivo and in vitro. We show that 
hypomethylation of the distal promoter region is correlated with definitive HSC 
potential in vivo, and can be promoted during in vitro hematopoietic differentiation 
by HOXB4. Concordantly, HOXB4 overexpression promotes P1 transcription and 
an increased P1/P2 mRNA ratio. Chromatin immunoprecipitation (chIP) analyses 
in mESC derived hematopoietic cells overexpressing HOXB4 show that P1 is 
preferentially bound by HOXB4, acquires histone modifications permissive to 
transcription, and undergoes a decrease in occupancy by the maintenance 
methyltransferase DNMT1. Thus, decreased methylation, acquisition of active 
chromatin modifications, and increased transcriptional activity at the P1 promoter 
is promoted in vitro via physical interaction with HOXB4.  
 
Materials and Methods 
ESC culture and differentiation 
mESC were cultured on irradiated murine embryonic fibroblasts (MEFs) in 
KO DMEM (Gibco) supplemented with 15% FBS, 0.1 mM nonessential amino 
acids (GIBCO), 2 mM glutamax, (Invitrogen), penicillin/streptomycin (Gibco), 0.1 
mM β-mercaptoethanol, and 1000 U/mL LIF(Millipore), at 37°C in 5% CO2. ES 
cells were differentiated as embryoid bodies (EB) as previously described119. 
Briefly, mESC were aggregated in hanging drops EB media consisting of IMDM 
supplemented with 15% FBS, 6 µM monothioglycerol (Sigma), 200 µg/ml human 
iron-saturated holo-transferrin (Sigma), 50 µg/ml ascorbic acid (Sigma), and 
penicillin-streptomycin (Gibco) in 5% CO2 at 37°C for 48 hrs. Hanging drop EBs 
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were transferred to 10 cm ultra-low adherence dish (Corning) in EB media and 
incubated on an orbital shaker at 70 rpm in 5% CO2 at 37°C. After an additional 
24 hours an 80% media change was performed and EBs were returned to 
shaking incubation for three days.  
OP9 co-culture and HOXB4 overexpression 
At day-6, EBs were dissociated and transduced with either MSCV-IRES-
GFP control or MSCV-HoxB4-IRES-GFP via spin infection at 2500 rpm for 1.5 
hrs followed by 4 hrs additional contact with viral supernatant. Cells were washed 
with PBS, and plated onto sub-confluent OP9 (Kindly provided by Dr. Mervin 
Yoder, Indiana University) in hematopoietic expansion (HE) media consisting of 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% FBS, 5 
ng/mL VEGF (Peprotech), 40 ng/mL TPO (Peprotech) , 40 ng/mL Flt-3L 
(Peprotech), penicillin/streptomycin (Gibco), 2 mM glutamax (Invitrogen) in 5% 
O2. Semi-adherent cells were passaged by trypsinization every 4-5 days. For 
histone and Dnmt1 chromatin immunoprecipitation experiments, a doxycyclin 
inducible HOXB4 mESC line was utilized87,119. CD41+ cells from day 6 embryoid 
bodies were collected for chIP analysis and the remainder were plated onto OP9 
with or without 500ng/ml doxycyclin and cultured as described above.  
Embryo dissection and cell isolation  
C57BL/6 mice were paired in the evening and the following morning (E0.5) 
females were checked for presence of vaginal plugs. Mice were housed in a 
specific pathogen-free facility and used with the approval of the University of 
Minnesota's institutional animal care committee. Yolk sac dissection and cell 
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preparation was performed as described120. Single cell suspensions from fetal 
liver were prepared as described previously121. 
Cell fractionation 
Fluorescence-activated cell sorting was performed using FACSAria. All 
antibodies were from eBioscience unless otherwise noted. Embryoid body and 
OP9 co-cultures were stained with c-Kit-APC (2B8), CD41-PE (Mwreg-30), and 
CD45-APC (30-F11). Fetal liver (FL) cells were stained with the following 
biotinylated monoclonal antibodies: Ter119 (TER-119), Gr-1 (RB6-8C5), CD3 
(500A2), and B220 (RA3-6B2), followed by incubation with anti-biotin microbeads 
(Miltenyi) according to manufacturer’s recommendations and depleted using an 
AutoMACS (Miltenyi). Lineage negative fraction was stained with CD48-FITC 
(TC15-12F12.2), CD150-PE (mShad), and Sca1-APC (D7). Yolk sac cells were 
enriched for CD41 by first labeling with CD41-PE antibody, followed by 
incubation with anti-PE microbeads and magnetic separation according to 
manufacturer recommendations (Miltenyi). Adult marrow KLS+SLAM cells were 
isolated by lineage depletion via MACS Lin Cell Depletion Kit (Miltenyi), per 
manufacturer protocol. Lineage negative fraction was then stained with c-Kit-APC 
(2B8), Sca-1-PE-Cy7 (D7), CD48-FITC (TC15-12F12.2), and CD150-PE 
(mShad) for 20 min @ 4 degrees per manufacturer protocol. Propidium iodide 
was used to exclude dead cells in all FACS purifications. 
Bisulfite sequencing and methylation analysis 
Genomic DNA was isolated using the DNeasy Blood and Tissue kit 
(Qiagen) according to manufacturer’s recommendations for isolation from 
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mammalian cells. Bisulfite conversion was performed using the Epitect Bisulfite 
kit (Qiagen) according to manufacturer’s protocol for low amounts of DNA. 
Primers were designed to specifically amplify converted DNA using the publicly 
available MethPrimer program (http://www.urogene.org/methprimer/index1.html). 
Single-step PCR amplification was conducted using Accuprime Supermix I or II 
(Invitrogen) for +23, and P1/P2 respectively. Amplification products were 
visualized by gel electrophoresis and bands were excised and purified using the 
QIAquick Gel Extraction kit (Qiagen). Purified PCR products were inserted into 
the PCR4-TOPO vector (Invitrogen) and individual clones were sequenced. 
Alignment and methylation analysis were performed using the online QUMA 
program (http://quma.cdb.riken.jp/). Sequenced clones with at least 90% non-
CpG cytosine conversion and at least 90% sequence homology were retained for 
analysis.  
Quantitative RT-PCR 
 OP9 co-cultures were collected and OP9 stromal cells were depleted via 
differential plastic attachment. RNA was isolated using the RNeasy Plus Micro kit 
(Qiagen). First-strand cDNA synthesis was performed using the Superscript VILO 
cDNA Synthesis kit (Invitrogen). Quantitative PCR was performed using Platinum 
SYBR Green qPCR Supermix (Invitrogen), and normalized to GAPDH. Primers 
used were described previously113.  
Chromatin immunoprecipitation 
 ChIP assays were performed according to previously described protocol 
with slight modifications122. OP9 co-cultures were collected via trypsinization and 
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OP9 cells were depleted via plastic attachment. Roughly 107 total cells were 
crosslinked for 10 min in 1% formeldahyde. Chromatin was sheared via 
sonication to generate fragments between 200-500 bp. The sonicated chromatin 
was incubated with the indicated antibodies overnight at 4°C and followed by 
incubation with 30 μl of Magna ChIP Protein A+G magnetic beads (Millipore) for 
2 hours. Beads were washed with RIPA buffer and TE buffer containing 50 mM 
NaCl. The immunoprecipitated complexes were eluted from the beads by heating 
at 65°C and reverse crosslinked by overnight incubation at 65°C. 
Immunoprecipitated DNA was treated with RNaseA and proteinase K, and 
purified using Qiagen PCR purification kit. Immunoprecipitations were performed 
using a rabbit anti-HoxB4 monoclonal (EP1919Y, Epitomics), rabbit anti-histone 
H3 Acetyl (K9) monoclonal (Y28, Epitomics), anti-H3K4me3 (ab8580, Abcam), 
anti-H3K27me3 (ab6002, Abcam), and anti-Dnmt1 (ab13537, Abcam). 
Immunoprecipitations were performed twice independently for each sample. 
Primers used for chIP-qPCR are available upon request. 
 
Statistics 
Statistical analysis of methylation between individual populations was 
performed using the online QUMA program (http://quma.cdb.riken.jp/). 
Differences between grouped methylation data were determined by unpaired 2-
tailed t test, with P values less than 0.05 considered significant. All other analysis 
was performed using a Student t test, with P value less than 0.05 considered 
significant. 
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Results 
Proximal Runx1 (P2) promoter is unmethylated regardless of lineage or 
developmental status  
The exceptionally large size of the Runx1 locus (224kb) limited our ability 
to perform locus-wide exploratory bisulfite sequencing. We thus focused on 
Runx1 regulatory elements previously confirmed to exhibit hematopoietic 
activity99 (Figure 1 A, Supplemental Table 1). The proximal Runx1 (P2) promoter 
is the most CpG dense (63% GC, 1.03 CpG observed/global expected) of the 
three Runx1 elements analyzed and the only one to contain a classic CpG island 
(GC > 50%, Obs/Exp > 0.6). To determine if the proximal Runx1 promoter is 
differentially methylated during hematopoietic development in vivo we analyzed 
bisulfite-treated genomic DNA from E14.5 mouse embryonic fibroblast cells 
(MEFs), E8.5 yolk sac (YS) CD41+ , E14.5 fetal liver (FL) Lin-Sca-1+CD48-
CD150+, and adult marrow Lin-c-Kit+Sca-1+CD150+CD48- (KLS+SLAM) cells; 
representing non-hematopoietic, primitive hematopoietic, and two stages of 
definitive HSC respectively (Figure 1 B, Supplemental Figure 1A-B). To parallel 
this analysis in vitro using mESC, we utilized an established two-stage 
differentiation process (Figure 1 B). mESC were first differentiated as embryoid 
bodies (EB) for six days to obtain primitive c-Kit+CD41+ progenitors 
(Supplemental Figure 2 A). Since HOXB4 overexpression is an efficient method 
to obtain ES-derived hematopoietic progenitors capable of robust long-term 
reconstitution post-transplant87, we utilized overexpression of HOXB4 and co-
culture on hematopoietic supportive OP9 stromal cells to obtain mESC-derived 
27 
 
definitive HSC. Day 6 EB cells were infected with MSCV-HOXB4-IRES-GFP or 
MSCV-IRES-GFP control virus and co-cultured on OP9 cells. The GFP+c-
Kit+CD45+ fraction was isolated from HOXB4 and control co-cultures after six 
days (6 + 6 days); and from HOXB4 co-cultures at eleven days (6 + 11 days) at 
which point no hematopoietic cells were observed in the control co-cultures 
(Supplemental Figure 2 B).  
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Figure 1.  
 
 
Figure 1. Runx1 genomic locus and cell populations for bisulfite analysis 
(A) Murine Runx1 locus and CpGs analyzed by bisulfite sequencing. For P1 
and P2 CpG# represents distance from transcription start site (TSS). For +23 
CpG# represents distance from 3’ end of PCR amplicon. (B) Cell populations 
isolated in vivo, and from ES cell differentiation strategy for bisulfite analysis. 
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In vivo, we find the proximal (P2) promoter to be unmethylated in MEFs, a 
non-hematopoietic control (0.8% ± 0.79%) (Figure 2 A). No change in P2 
promoter methylation was associated with primitive hematopoiesis as P2 was 
also unmethylated in E8.5 YS CD41+ cells (1.7% ± 0.85%) (Figure 2 A). This 
absence of P2 promoter methylation continues in E14.5 FL Lin-Sca-1+CD48-
CD150+ cells (3.1% ± 1.63%), and in adult marrow KLS+SLAM (0% ± 0%) 
(Figure 2 A), indicating that the Runx1 proximal (P2) promoter does not exhibit 
differential methylation between lineages, or during hematopoietic development 
in vivo. While previous reports indicate a P1 bias in FL and adult HSC101,106,113, 
our data indicate that the methylation status of the P2 promoter does not 
establish this bias.  
The absence of P2 promoter methylation was mirrored in vitro in 
undifferentiated mESC (1.4% ± 0.91) and did not change in day 6 EB c-
Kit+CD41+ cells (2.1% ± 1.02) (Figure 2 B). P2 remained unmethylated in day 6 
+ 6 OP9 co-cultures in both control c-Kit+CD45+ cells (2.2% ± 1.79), as well as 
HOXB4 overexpressing cells at day 6+6 (0.6% ± 0.56) and day 6 + 11 (1.2% ± 
0.82) (Figure 2 B). These observations are consistent with previous reports that 
CpG dense core promoter regions are predominantly unmethylated123,124, and 
that P2 expression exhibits a lower degree of lineage restricted expression than 
P1 during development125. Indeed, global DNA methylation data released by the 
ENCODE Consortium confirms a foci of hypomethylation at the P2 promoter in 
multiple cell lineages126. 
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Figure 2.  
Figure 2. Bisulfite analysis of proximal Runx1 promoter 
(A) Methylation patterns of the Runx1 proximal (P2) promoter in cells derived 
from E14.5 murine embryonic fibroblast cells (MEFs), E8.5 yolk sac (YS) 
CD41+ (E8.5 YS), E14.5 FL Lin-Sca-1+CD48-CD150+ (E14.5 FL), and adult 
marrow Lin-c-Kit+Sca-1+CD150+CD48- (KLS+SLAM). Sequencing reactions 
of individual amplicons are represented by each row of circles. Open circles 
denote unmethylated CpGs, and filled circles represent methylated CpGs. (B) 
Methylation patterns in murine ES cells (mESC), day 6 embryoid body c-
Kit+CD41+ (D6 EB) and from OP9 co-cultures: GFP+c-Kit+CD45+ cells 
isolated from IRES-GFP control group at day 6 (D6+6 Control); and HOXB4-
IRES-GFP group at day 6 (D6+6 HoxB4) and day 11 (D6+11 HoxB4). 
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Hypomethylation of the +23 enhancer correlates with the hematopoietic 
lineage  
The recently described intronic +23 enhancer element has been shown to 
drive hematopoietic specific transcription99. Sequence analysis of this region 
shows low CpG density and does not specify a classic CpG island (58% GC, 
0.31 Obs/Exp). In vivo, we find the +23 enhancer is highly methylated in MEFs 
(79.4% ± 4.66), but methylation is significantly decreased in E8.5 YS CD41+ cells 
(1.7% ± 1.22), E14.5 FL Lin-Sca-1+CD48-CD150+ (18.8% ± 8.29), and adult 
KLS+SLAM (4.2% ± 2.54) (Figure 3 A-B). These results demonstrate that +23 
enhancer hypomethylation occurs during embryonic hematopoiesis and 
continues into fetal and adult hematopoiesis.  
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Figure 3. 
Figure 3. Bisulfite analysis of +23 enhancer methylation  
(A) Methylation patterns of the Runx1 +23 enhancer in cells from in vivo-
derived E14.5 murine MEFs, E8.5 YS CD41+ (E8.5 YS), E14.5 FL Lin-Sca-
1+CD48-CD150+ (E14.5 FL), and adult marrow Lin-c-Kit+Sca-
1+CD150+CD48- (KLS+SLAM). Sequencing reactions of individual amplicons 
are represented by each row of circles. Open circles denote unmethylated 
CpGs, and filled circles represent methylated CpGs. (B) Quantification of 
%CpG methylation at +23 in hematopoietic populations derived in vivo, ***P < 
.001, **.001 < P < .01, *.01 < P < .05. (C) Methylation patterns in mESC day 6 
embryoid body c-Kit+CD41+ (D6 EB) and from OP9 co-cultures: GFP+c-
Kit+CD45+ cells isolated from IRES-GFP control group at day 6 (D6+6 
Control); and HOXB4-IRES-GFP group at day 6 (D6+6 HoxB4) and day 11 
(D6+11 HoxB4). (D) Quantification of %CpG methylation at +23 in cell 
populations isolated during hematopoietic differentiation of mESC, ***P < 
.001, **.001 < P < .01, *.01 < P < .05. 
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This correlation of +23 hypomethylation and the hematopoietic lineage also 
occurs during hematopoietic differentiation of mESC. The +23 enhancer is 
methylated to a high degree in undifferentiated mESCs (84.7% ± 4.23), followed 
by a significant decrease in day 6 EB c-Kit+CD41+ hematopoietic cells (6.9% ± 
1.81) that is maintained in OP9 co-cultured control c-Kit+CD41+ cells at day 6 + 
6 (11.4% ± 11.1) and in HOXB4 overexpressing cells at both day 6 + 6 (2.5% ± 
1.81) and day 6 +11 (5% ± 1.64) (Figure 3 C-D). To further define the 
hematopoietic specificity of +23 hypomethylation, we compared the +23 
methylation profile of day 6 EB c-Kit+CD41- cells to that of day c-Kit+CD41+ cells 
since CD41 is the earliest known marker of hematopoiesis47,127. We found that 
+23 hypomethylation strongly correlated with the acquisition of hematopoietic 
fate as defined by CD41 (70.9% ± 6.1 vs. 6.9% ± 1.81, P = 0.0002) (Figure 4 A). 
In contrast, there is no statistically significant difference in the methylation of the 
distal promoter between these populations (Figure 4 B).  
Enhancer methylation has been shown to influence gene expression128. 
We examined the expression of the P1 and P2 mRNA in day 6 EB c-Kit+CD41- 
and c-Kit+CD41+ cells, and found that both P1 and P2 transcriptional activities 
are increased in c-Kit+CD41+ cells (Figure 4 C). Thus, +23 methylation 
influences the activity of both Runx1 promoters in a manner that correlates with 
CD41 acquisition.  
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Figure 4.  
 
Figure 4. Bisulfite analysis and Runx1 expression in day 6 EB 
subpopulations 
(A) Methylation patterns of the Runx1 +23 enhancer in c-Kit+CD41- and c-
Kit+CD41+ cells from day 6 EBs. (B) Methylation patterns of the Runx1 distal 
(P1) promoter in c-Kit+CD41- and c-Kit+CD41+ cells from day 6 EBs. (C) RT-
qPCR analysis of Runx1 P1 and P2 mRNA isoforms in c-Kit+CD41- and c-
Kit+CD41+ cells from day 6 EBs. 
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Distal Runx1 (P1) promoter hypomethylated in HSC in vivo 
 Several studies have observed that expression of the P1 Runx1 mRNA 
isoform is specifically upregulated in definitive hematopoietic cells during 
development, and comprises the majority of Runx1 transcript in HSC101,106,113. 
While the proximal P2 promoter is CpG dense and structurally similar to 
housekeeping promoter elements100, the distal P1 promoter is more complex in 
terms of transcription factor binding sites and comparatively CpG poor (46% GC, 
0.25 Obs/Exp). Consistent with the definitive hematopoiesis-specific activity of 
the P1 promoter, a high degree of methylation is observed in MEFs (86.3% ± 
3.76) (Figure 5 A-B). Compared to MEFs, there is a modest yet statistically 
significant decrease in P1 promoter methylation in E8.5 YS CD41+ (48.6% ± 
5.45) (Figure 5 A-B). However, an even greater degree of P1 hypomethylation is 
observed in definitive HSC, where E14.5 FL Lin-Sca-1+CD48-CD150+ (8.1% ± 
3.89) and KLS+SLAM (9% ± 5.65) cells exhibit a significantly lower level of P1 
methylation compared to E8.5 YS CD41+ cells (Figure 5 A-B).  
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Figure 5.  
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Figure 5. Bisulfite analysis and mRNA expression from distal Runx1 
promoter 
(A) Methylation patterns of the Runx1 distal (P1) promoter in cells from in 
vivo-derived E14.5 MEF, E8.5 YS CD41+ (E8.5 YS), E14.5 FL Lin-Sca-
1+CD48-CD150+ (E14.5 FL), and adult marrow Lin-c-Kit+Sca-
1+CD150+CD48- (KLS+SLAM). Sequencing reactions of individual amplicons 
are represented by each row of circles. Open circles denote unmethylated 
CpGs, and filled circles represent methylated CpGs. (B) Quantification of 
%CpG methylation at P1 in hematopoietic populations derived in vivo, ***P < 
.001, **.001 < P < .01, *.01 < P < .05. (C) Methylation patterns in mESC, day 
6 embryoid body c-Kit+CD41+ (D6 EB) and from OP9 co-cultures: GFP+c-
Kit+CD45+ cells isolated from IRES-GFP control group at day 6 (D6+6 
Control); and HOXB4-IRES-GFP group at day 6 (D6+6 HoxB4) and day 11 
(D6+11 HoxB4). (D) Quantification of %CpG methylation at P1 in cell 
populations isolated during hematopoietic differentiation of mES cells, ***P < 
.001, **.001 < P < .01, *.01 < P < .05. (E) P1 mRNA/P2 mRNA levels after 
normalization to Gapdh over the course of hematopoietic differentiation in 
vitro. 
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HoxB4 alters P1 promoter methylation and transcriptional activity in vitro 
 We next determined whether this in vivo epigenetic signature of definitive 
HSC is replicated during mESC differentiation. Like the +23 enhancer, P1 is 
highly methylated in undifferentiated mESC (90% ± 3.3) (Figure 5 C-D). 
Paralleling our results in vivo, a modest decrease is observed in day 6 EB c-
Kit+CD41+ cells (68.9% ± 5.65) and in OP9 co-cultured control c-Kit+CD45+ 
cells at day 6 + 6 (71.6% ± 7.06) (Figure 5 C-D). However, in OP9 co-cultured c-
Kit+CD45+ cells overexpressing HOXB4, we observe a significant decrease in 
P1 methylation compared to control cells at day 6 + 6 (47.8% ± 5.4), followed by 
a further decrease by day 6 + 11 (27% ± 5.08), corresponding to a population 
shown to possess more robust hematopoietic repopulating potential after 
adoptive transfer in vivo (Figure 5 C-D). These data demonstrate that the Runx1 
P1 promoter is methylated in pluripotent mESC and remains methylated in the 
first wave of c-Kit+CD41+ hematopoietic progenitors. Maturation to c-Kit+CD45+ 
progenitors on OP9 alone does not change this methylation profile, whereas 
overexpression of HOXB4 during this process results in decreased P1 
methylation. 
 To determine whether P1 hypomethylation is linked to promoter switching 
during differentiation, we examined relative P1 vs. P2 mRNA levels using isoform 
specific quantitative RT-PCR. As expected, P2 dominates in primitive EB-derived 
cell populations and in OP9 control co-cultures (Figure 5 E). However, the P1/P2 
ratio is higher in HoxB4 overexpressing OP9 co-cultures, and even higher in 
purified c-Kit+CD45+ hematopoietic cells overexpressing HoxB4 (Figure 5 E). 
39 
 
These data suggest that HoxB4 induced P1 hypomethylation is associated with a 
consequent increase in the P1/P2 mRNA ratio in vitro.  
HoxB4 directly activates the Runx1 P1 promoter  
It was unclear whether the mechanism underlying HOXB4-mediated 
activation of P1 was direct, or indirect. To examine this question, we performed 
chIP analysis in ESC derived hematopoietic cells during differentiation to 
examine the level of HOXB4 binding at Runx1 regulatory regions. We find that 
HOXB4 preferentially binds the P1 promoter upon overexpression at D6+6 and 
D6+11, thus identifying a direct role for HOXB4 in the modulation of P1 
transcriptional activity (Figure 6 A).  
We next explored changes in chromatin organization over the time-course 
of hematopoietic differentiation. Bivalency of lineage-specific genes is a hallmark 
of pluripotency and involves the co-localization of active (H3K4me3) and 
repressive (H3K27me3) histone modifications which subsequently resolve to the 
presence of one or the other during lineage commitment129. We find that 
H3K27me3 is uniformly absent at P1, +23, and P2 as compared to a silenced 
control region (Pitx1) at all time-points, demonstrating that the Runx1 locus is 
primed for activation early in the hematopoietic lineage and is not altered by 
HOXB4 overexpression (Figure 6 B). Consistent with our expression data, 
H3K4me3 is enriched at the P2 promoter and an active control locus (Gapdh) 
over the course of differentiation and is not altered by HOXB4 (Figure 6 B). 
Conversely, H3K4me3 presence at the P1 promoter is significantly increased 
upon overexpression of HOXB4 by D6+6 and is maintained through D6+11 
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(Figure 6 B). Finally, we find that H3K9Ac – a mark of actively transcribed 
promoters – is present throughout differentiation at P2, but is significantly 
increased at P1 only in D6+11 HoxB4 overexpressing cells (Figure 6 C); a finding 
that is consistent with both our methylation and expression data in that this time-
point coincides with the highest degree of P1 hypomethylation and maximal level 
of P1 expression in vitro130. From these collective results, we conclude that 
HOXB4 preferentially binds to the Runx1 P1 promoter, and stimulates 
transcription via decreased methylation and establishment of a permissive 
chromatin state in ESC derived hematopoietic cells.  
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Figure 6. 
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Figure 6. Runx1 chIP analysis 
(A) Quantitative PCR analysis of chromatin immunoprecipitation performed 
against HOXB4. Data were normalized to the percent of pre-
immunoprecipitation input for each sample, and are expressed as the fold 
change versus the D6+6 control population. Data are representative of at 
least two independent immunoprecipitations. (B) Quantitative PCR analysis of 
chromatin immunoprecipitation performed against H3K4me3 and H3K27me3. 
Data are expressed as the percent of pre-immunoprecipitation input for each 
sample and are representative of at least two independent 
immunoprecipitations, ***P < .001, **.001 < P < .01, *.01 < P < .05.  
(C) Quantitative PCR analysis of chromatin immunoprecipitation performed 
against H3K9Ac. Data are expressed as the percent of pre-
immunoprecipitation input for each sample and are representative of at least 
two independent immunoprecipitations, ***P < .001, **.001 < P < .01, *.01 < P 
< .05. (D) Quantitative PCR analysis of chromatin immunoprecipitation 
performed against Dnmt1. Data are expressed as the fold change versus 
Gapdh control locus for each sample and are representative of at least two 
independent immunoprecipitations, ***P < .001, **.001 < P < .01, *.01 < P < 
.05. 
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Dnmt1 occupancy at P1 is decreased in HOXB4 overexpressing cells 
DNA methylation patterns are either maintained during replication via the 
activity of the maintenance methyltransferase DNMT1, or established de novo by 
DNMT3a and DNMT3b131-133. To determine whether the loss of methylation at P1 
is accompanied by decreased interaction with members of the DNA 
methyltransferase family, we measured the level of DNMT1, DNMT3a, and 
DNMT3b occupancy at the Runx1 promoters. We did not detect binding of 
DNMT3a or DNMT3b to P1 (data not shown), however we found that DNMT1 did 
interact with P1, and this interaction was significantly decreased at D6+11 in 
HOXB4 overexpressing cells (Figure 6 D). As expected, occupancy was 
universally low at the hypomethylated P2 promoter at all time-points (Figure 6 D). 
These data are consistent with a mechanism in which DNMT1 is occluded from 
accessing the P1 promoter in the presence of HOXB4, resulting in a gradual loss 
of established methylation patterns over subsequent cell divisions. 
 
Runx1 P1 methylation as signature of definitive HSC 
Finally, to compare our in vivo and in vitro observations that P1 
methylation is correlated with definitive HSC during development we grouped all 
cell populations studied based on whether or not they are known to possess 
hematopoietic repopulating capacity and compared mean levels of P1 promoter 
methylation. This comparison indicated that P1 promoter hypomethylation 
correlated with repopulating capacity in a similar fashion in vivo and in vitro 
(Figure 7 A). To increase the resolution of P1 promoter demethylation we applied 
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the same grouped comparison to the individual CpG dinucleotides in the P1 
promoter and found that overall methylation was significantly decreased for each 
CpG, with the exception of the CpG located at position -371 relative to the P1 
transcription start site. In particular, the CpGs located at position -436 and -271 
were the most significantly different between repopulating and non-repopulating 
cell types (Figure 7 B).  
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Figure 7. 
 
Figure 7. Comparison of P1 methylation in repopulating and non-
repopulating cell types 
(A) %CpG methylation at P1 promoter in repopulating (R) and non-
repopulating (NR) cell populations. Bar indicates the mean, ***P < .001, 
**.001 < P < .01, *.01 < P < .05; unpaired t test. (B) Percent methylation at 
individual CpG within P1 promoter in repopulating (R) and non-repopulating 
(NR) cell populations. Bar indicates the mean, ***P < .001, **.001 < P < .01, 
*.01 < P < .05; unpaired t test. 
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Discussion 
 Here, we identify previously un-described changes in DNA methylation at 
Runx1 regulatory regions during hematopoietic development. These changes are 
associated with commitment to the hematopoietic lineage, and distinguish 
definitive repopulating HSC populations from earlier, primitive non-repopulating 
cells. We find that the CpG dense proximal P2 promoter is unmethylated in 
mESC, and remains unmethylated regardless of lineage and stage of 
hematopoietic development. Conversely, the +23 intronic enhancer is methylated 
in mESC, non-hematopoietic fibroblasts, and c-Kit+CD41- cells from day 6 EBs, 
but is dramatically hypomethylated upon acquisition of CD41 and remains 
unmethylated throughout hematopoietic development. Importantly, we 
demonstrate that hypomethylation of the distal P1 Runx1 promoter is specific to 
cell populations enriched in definitive repopulating capacity in vivo. Moreover, in 
mES-derived c-Kit+CD41+ hematopoietic progenitors, the distal P1 promoter 
remains methylated at similar levels to that observed in E8.5 YS. Overexpression 
of HOXB4 results in a significant decrease in P1 methylation consistent with its 
ability to generate mES-derived hematopoietic progenitors capable of long-term 
repopulation in transplant recipients87. Thus, our results identify hypomethylation 
of the distal Runx1 promoter as a novel epigenetic signature of repopulating 
hematopoietic cells during development, and provide critical insight into the 
dynamic epigenetic changes influencing the Runx1 locus.  
The developmental processes leading to the formation of definitive HSC 
rely on the properly orchestrated activity of a complex network of critical 
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transcription factors to guide genetic programs associated with differentiation. 
Runx1 is a critical transcription factor involved in the development of definitive 
HSC95,96,110 and, not surprisingly, is frequently dis-regulated in hematopoietic 
malignancy94,111. A diverse array of Runx1 mRNA isoforms have been 
identified134, and arise through a combination of alternative splicing as well as 
alternate promoter usage100,101,112,135. As methods for genome-wide analysis of 
CpG methylation have improved, a growing number of TDMR associated with 
normal and abnormal development have been identified136. Previously, it was 
unknown whether the Runx1 regulatory regions are TDMR. In the case of the 
Runx1 proximal P2 promoter, our data now indicate it is not a TDMR as P2 is 
unmethylated in a wide array of cell types. This observation is consistent with 
previous reports at other CpG rich core promoters123,124, and is supported by 
genome wide DNA methylation profiles released by the ENCODE Consortium126. 
That the P2 methylation pattern is established at the pluripotent stage, and does 
not change in differentiated cell types or during hematopoietic development 
suggests that methylation of the P2 does not influence lineage specific changes 
in P2 transcription during development. It seems unlikely that P2 methylation acts 
as an “on/off” switch since the P2 isoform is detected in a diverse array of cell 
types125, including undifferentiated mESCs137, and the P2 promoter remains 
unmethylated in FL and adult HSC even though P1 is the dominant promoter in 
these populations101,106,113. Therefore, our observations suggest that P2 
methylation is not involved in the lineage restriction of P2 during development. 
Intriguingly, intragenic TDMR 3’ of P2 have been identified, raising the possibility 
48 
 
that methylation at these regions could have a role in the regulation of P2 
activity114. 
In contrast to the proximal promoter, the +23 intronic enhancer is a TDMR, 
and while the hematopoietic specific activity of the Runx1 +23 enhancer element 
is documented99, our data are the first to identify changes in CpG methylation at 
the +23 enhancer element during hematopoietic development. Previous data 
indicating that methylation of intronic enhancer elements influences tissue-
specific gene expression128, further supports a role for +23 enhancer methylation 
in the transcriptional activity of Runx1. We confirm this hypothesis by clearly 
demonstrating that +23 hypomethylation strongly correlates with increased 
transcription at both Runx1 promoters at the earliest stage of hematopoietic 
development, though P2 remains the dominant mRNA isoform in these 
populations. There is evidence that intragenic DNA methylation influences 
alternate promoter usage118, however our observations indicate that +23 
hypomethylation is not a significant factor in the observed P1/P2 switch, but 
rather acts as an epigenetic rheostat for the Runx1 locus, mediating 
hematopoietic specific amplification of Runx1 expression. We cannot rule out the 
possibility that +23 hypomethylation facilitates a more permissive state for P1 
transcription by allowing improved mRNA elongation138, though this does not fit 
our observation that +23 enhancer methylation is lost early in development when 
P2 still dominates compared to adult HSC101,113. Considering our data that P1 
hypomethylation results in a shift to P1 biased expression, a more probable 
explanation is that +23 methylation is a non-biased regulator of transcription from 
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both promoters, and the usage bias is determined by the epigenetic status of P1. 
Studies utilizing clonal cell populations with well-defined mRNA isoform 
expression profiles, or episomal reporters in which methylation can be artificially 
manipulated might help to refine the role of methylation in regulating promoter 
usage, however the utility of these assays is limited by the lack of developmental 
and genomic context. Regardless, our data clearly demonstrate that +23 
methylation influences its enhancer capacity, and provide a novel epigenetic 
signature of the hematopoietic lineage which can be applied to optimize methods 
for direct conversion of other lineages to a hematopoietic fate139.  
Derivation of robust numbers of in vivo long-term repopulating HSC from 
pluripotent cell sources such as ES and induced pluripotent stem cells is of 
therapeutic interest. Critical to the success of these efforts is the identification of 
signatures associated with the formation of definitive HSC during development. 
While their precise role in the regulation of gene transcription is not-fully 
understood, TDMR and differential DNA methylation has nonetheless proven 
useful for identifying differences in cell populations. This is highlighted by the 
utilization of DNA methylation patterns to determine whether somatic cells have 
been successfully reprogrammed to a pluripotent state140,141. We have identified 
the P1 distal Runx1 promoter as a novel TDMR, and demonstrate that 
hypomethylation of this region differentiates primitive non-repopulating 
progenitors and definitive repopulating HSC during embryonic development in 
vivo. Our observation that unmodified hematopoietic progenitors derived from 
mESC do not undergo this decrease in P1 methylation suggests a failure in the 
50 
 
epigenetic transition to adult-type definitive hematopoiesis. By overexpressing 
HOXB4 in ESC derived hematopoietic cells we show it is possible to promote 
epigenetic remodeling of the Runx1 locus during differentiation of ESC to 
hematopoietic cells in vitro. The hypomethylation of P1 induced by HOXB4 
results in an increased P1/P2 mRNA ratio, and thus links P1 hypomethylation to 
the P2 to P1 promoter switch observed during hematopoietic development. 
Mechanistically, we show that when overexpressed, HOXB4 preferentially binds 
P1, supporting a model in which the epigenetic remodeling and increased 
transcription of P1 is mediated via physical interaction of HOXB4 with this locus. 
Recent HOXB4 chIP-Seq data support our findings that HOXB4 interacts with the 
Runx1 distal promoter, albeit using a slightly different ESC differentiation method, 
suggesting that this is a robust biological phenomenon93. Whether demethylation 
of P1 in the presence of HoxB4 is an active or passive process remains unclear. 
However our observation that P1 methylation is only slightly decreased at D6+6 
and becomes more pronounced by D6+11 is congruent with a passive loss of 
methylation. This is supported by reports finding that active demethylation often 
occurs rapidly—within minutes or hours, and results in nearly complete de-
methylation of the region in question142,143. As HOXB4 physically binds Runx1 
P1, it is conceivable that HOXB4 or a HOXB4-associated complex could 
physically or functionally occlude the activity of factors involved in maintaining 
DNA methylation, such as Dnmt1. Indeed, our data demonstrating a decrease in 
Dnmt1 occupancy of P1 in HOXB4 overexpressing cells is consistent with this 
model. Over successive rounds of DNA replication this would result in a loss of 
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Runx1 P1 methylation. Previous reports that differentiation induced 
hypomethylation of lineage specific CpG-poor promoters correlate with 
transcription factor binding further supports this explanation144. 
The fact that epigenetic remodeling of P1 could be achieved by 
overexpressing HOXB4 demonstrates that this in vivo epigenetic signature is 
valid during ES cell differentiation and can potentially be replicated if the 
appropriate extracellular cues are applied during the differentiation process, 
whether in vivo or in vitro, via the induction of appropriate transcription factor 
circuits. Our single CpG group analysis identifies the CpGs located -436 and -
271 from the P1 transcription start site as the most significantly hypomethylated 
in definitive repopulating cell populations, and presents an attractive target for 
high-throughput analysis of changes in P1 methylation during hematopoietic 
differentiation of ESC/iPS.  
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Supplemental Tables 
Table S1. Bisulfite primers and amplicon properties 
Locus Forward Primer Reverse Primer 
Amplic
on Size #CpGs 
P1 
TGTTTTTATTAAGAATTTAGT
TTTTT 
CTTTTCTTACTCTCTCTATCCTA
TAC 219bp 5 
+23 
ACTACTACAAAAACAAACTA
CCCAC 
TTTTTAAAGAGTTTGGGATGTT
GATA 151bp 8 
P2 
TGATTTTTAGGTTTAGGGTTT
TTT AACCCAAATTCAAATCCCAC 184bp 18 
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Supplemental Figures 
Figure S1. 
 
Figure S1. Surface antigen profiles and purification of E14.5FL and 
KLS+SLAM.  
(A) Representative surface antigen profile and gating strategy used to enrich 
Sca-1+CD48-CD150+ from E14.5 FL after magnetic bead depletion of lineage 
positive fraction. (B) Isolation of linage negative c-Kit+Sca-1+CD48-CD150+ 
(KLS+SLAM) fraction from adult marrow after magnetic bead depletion of 
lineage positive fraction. 
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Figure S2 
 
 
Figure S2. Surface antigen profiles and purification of hematopoietic 
populations from ES cell differentiations.  
(A) Surface antigen profile and FACS purification of c-Kit+CD41- and c-
Kit+CD41+ cell fractions from day 6 EBs. (B) Representative surface antigen 
profile and gating strategy used to isolate GFP+c-Kit+CD45+ population from 
OP9 co-cultures. 
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Chapter 3. 
Targeted single copy Runx1 reporter mESC lines for interrogation and 
enhancement of definitive hematopoiesis from mESC 
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Foreward 
 The association of Runx1 promoter switching with formation of definitive 
HSC provides a unique molecular signature with which to characterize definitive 
hematopoietic cells during in vitro differentiation of PSC. We generated clonal 
mESC lines harboring targeted, single copy fluorescent reporter constructs under 
transcriptional control of combinations of known Runx1 regulatory elements. In 
this system, the P1 and P2 promoters are capable of directing subtly different, 
but hematopoietic specific transcription. The strength and specificity of each 
promoter is increased by the +23 enhancer, though this effect is biased toward 
the activity of the associated promoter. Dual-fluorescent and bio-luminescent 
reporter constructs containing all elements in their appropriate cis context 
accurately reflected endogenous Runx1 promoter switching. Day 8 embryoid 
body subpopulations delineated by promoter activity exhibited unique surface 
antigen profiles and differ in their expression of key hematopoietic transcriptions 
factors. We find that virtually all multi-potential CFC in day 8 embryoid bodies are 
contained within the P1+ population, and identify specific stromal based co-
culture conditions that allow the expansion of hematopoietic progenitors within 
this population.  Our dual-bioluminescent reporter allows non-invasive and highly 
sensitive analysis of Runx1 expression, making it ideal for high-throughput 
screening applications.  Altogether, our novel dual-promoter reporter mESC lines 
provide a new platform for identifying conditions promoting definitive 
hematopoiesis, and the compact nature of our synthetic reporter constructs will 
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allow their rapid transfer into knockout mESC lines and disease model derived 
induced pluripotent stem cells (iPSC) for further investigation.  
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Introduction 
 Pluripotent stem cells (PSC) have the potential to serve as a renewable 
source of hematopoietic stem cells (HSC) for transplant, however current 
differentiation strategies are biased toward the generation of primitive 
hematopoietic cells that are incapable of long-term multilineage engraftment 
posttransplant.  As many phenotypic and molecular pathways are shared by 
primitive and definitive hematopoiesis, identification of discrete signatures of 
each has been difficult.  Long-term engraftment remains the gold standard 
benchmark for definitive HSC, but is inherently retrospective and logistically 
taxing; thus restricting its application to very low throughput screens.  Efforts to 
enhance specification toward definitive hematopoiesis would be fostered by the 
development of new phenotypic and molecular signatures that distinguish 
definitive from primitive waves of hematopoiesis; particularly those that are 
amenable to high-throughput screens and/or prospective isolation of rare 
definitive progenitors during in vitro differentiation.   
 The runt-related transcription factor, Runx1, is specifically required in 
hemogenic endothelium for successful transition to HSC during embryonic 
development, and is thus a useful genetic indicator of the hematopoietic lineage 
during in vitro differentiation of PSC71,145. Its utility as a specific indicator of 
definitive hematopoiesis is precluded however, by the fact that it is also 
expressed in early yolk-sac, prior to the formation of intra-embryonic definitive 
HSC101,103. Transcription of the Runx1 locus can be further subdivided based on 
the activities of alternative proximal (P2) and distal (P1) promoter elements 
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104,134,135. Interestingly, the transcriptional activity of these promoters is 
developmentally regulated, such that the activity of the proximal promoter 
predominates in primitive hematopoiesis and hemogenic endothelium, while the 
distal promoter becomes active only in definitive hematopoietic progenitors, and 
is the dominant promoter in fetal liver (FL) and adult HSC101-103,112,146.  In light of 
this observation, P1 promoter activity and the presence of its associated mRNA 
isoform, Runx1c, would serve as a useful indicator of the onset of definitive 
hematopoiesis during PSC differentiation.  
 The exploitation of P1 driven Runx1 expression as a novel molecular 
signature of definitive hematopoiesis is hampered by the fact that, as an 
intracellular transcription factor, it can only be detected by RT-PCR of Runx1c 
mRNA, or by intracellular staining of the associated protein isoform; neither of 
which is amenable to the prospective isolation of viable cells for subsequent 
characterization.  To circumvent this issue, the regulatory elements of the P1 
promoter could be co-opted to drive the expression of proteins that are more 
readily detectable without the need for cell disruption, i.e. fluorescent, 
bioluminescent, and membrane bound proteins. Indeed, minimal regulatory 
regions of both the P1 and P2 promoters have been identified, however in 
plasmid based reporter assays and in transgenic animals, neither promoter was 
capable of driving hematopoietic transcription 99,100.  Instead, hematopoietic 
specificity of each promoter relied on the presence of an enhancer element (+23) 
located within the first intron99.  This element was capable of driving 
hematopoietic specific transcription from both P1, P2, and a heterologous 
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promoter element via its interaction with Gata2, Ets factors, and the 
SCL/Lmo2/Ldb1 complex98.  Unfortunately, these studies did not identify a setting 
in which the specific activity of the P1 promoter element could be replicated. 
Alternatively, Sroczynska et al. took the approach of targeting reporter encoding 
cDNAs to the P1 and P2 loci in murine embryonic stem cells (mESC), which 
effectively allowed the dissection of their discrete activities during in vitro and in 
vivo hematopoietic development103.  This elegant study confirmed the definitive 
specific activity of the P1 promoter and allowed the prospective isolation of P1+ 
cells by fluorescence activated cell sorting (FACS), however this approach 
requires two laborious gene targeting steps and is thus impractical for application 
in knockout mESC lines and disease model derived induced pluripotent stem 
cells (iPSC); applications which would be valuable to the investigation of novel 
regulatory pathways involved in the specification of definitive hematopoiesis and 
the effects that certain diseases have on this process.  In addition, knock in 
strategies usually disrupt one allele of the gene in question, which may have 
unintended consequences. This is particularly true for Runx1, as its expression 
levels are tightly regulated and autoregulatory mechanisms have been 
identified135,147.  Not surprisingly, Runx1 haploinsufficiency has documented 
biological consequences148,149 .  The development of synthetic, readily 
transferrable reporter constructs that recapitulate the Runx1 promoter switch 
would overcome many of these limitations.  
 In the present study, we used an mESC line that allows efficient targeting 
of DNA constructs to the transgene permissive hypoxanthine guanine 
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phoshoribosyl transferase 1 (Hprt) locus to generate a panel of clonal mESC 
lines harboring single copy fluorescent reporter constructs under the 
transcriptional control of different combinations of Runx1 regulatory elements 119.  
Using these lines, we find that endogenous Runx1 promoter switching is 
accurately reported when the P1, +23, and P2 regulatory elements are in cis, and 
in their appropriate genomic orientation.  Our dual fluorescent and 
bioluminescent reporter mESC lines allowed the non-invasive monitoring and 
prospective isolation of cell populations based on promoter activity. These 
subfractions were distinct in their surface antigen profiles and in the expression 
of key hematopoietic transcription factors. We found that the P1+ population 
contained nearly all multi-potential colony-forming cells (CFC) in day 8 EBs, and 
exhibited the most robust hematopoietic expansion in stromal based co-cultures. 
Finally, we demonstrate the utility of this system by identifying a specific set of 
culture conditions that are most effective in expanding hematopoietic progenitors 
from the P1+ population.  
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Materials and Methods 
Generation of p2Lox reporter constructs 
P1, P2, and +23 constructs were cloned from genomic DNA by PCR using 
primers that were previously described99. Creation of reporter constructs was 
performed using standard overlap based isothermal assembly150, and inserted 
into PacI and Not1 linearized p2Lox. Primers used for cloning are available upon 
request. 
ESC culture, differentiation, and genetic modification 
mESC were cultured on irradiated murine embryonic fibroblasts (MEFs) in 
KO DMEM (Gibco) supplemented with 15% FBS, 0.1 mM nonessential amino 
acids (GIBCO), 2 mM glutamax, (Invitrogen), penicillin/streptomycin (Gibco), 0.1 
mM β-mercaptoethanol, and 1000 U/mL LIF(Millipore), at 37°C in 5% CO2. ES 
cells were differentiated as embryoid bodies (EB) as previously described119. 
Briefly, mESC were aggregated in hanging drops EB media consisting of IMDM 
supplemented with 15% FBS, 6 µM monothioglycerol (Sigma), 200 µg/ml human 
iron-saturated holo-transferrin (Sigma), 50 µg/ml ascorbic acid (Sigma), and 
penicillin-streptomycin (Gibco) in 5% CO2 at 37°C for 48 hrs. Hanging drop EBs 
were transferred to 10 cm ultra-low adherence dish (Corning) in EB media and 
incubated on an orbital shaker at 70 rpm in 5% CO2 at 37°C. After an additional 
24 hours an 80% media change was performed and EBs were returned to 
shaking incubation for three days. For two-dimensional HE cultures, day 4 Flk1+ 
cells were plated onto gelatin coated plates in the indicated media and assessed 
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48hr later. Inducible cassette exchange mediated targeting of reporter constructs 
to Hprt was performed as previously described119.  
Stromal co-culture and HOXB4 overexpression 
AGM stromal lines were maintained as previously described151. For co-
culture experiments, day 8 EB derived mCherry+GFP+ cells were plated onto 
sub-confluent stroma in hematopoietic expansion (HE) media consisting of 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% FBS, 5 
ng/mL VEGF (Peprotech), 40 ng/mL TPO (Peprotech) , 40 ng/mL Flt-3L 
(Peprotech), and where indicated, 20 ng/ml Il-3 and IL-6; penicillin/streptomycin 
(Gibco), 2 mM glutamax (Invitrogen) in 5% O2.  For HoxB4 overexpression 
experiments, day 6 EBs were dissociated and transduced with either MSCV-
IRES-GFP control or MSCV-HoxB4-IRES-GFP via spin infection at 2500 rpm for 
1.5 hrs followed by 4 hrs additional contact with viral supernatant. Cells were 
washed with PBS, and plated onto sub-confluent OP9 in HE media 
supplemented with 10% FBS, 5 ng/mL VEGF, 40 ng/mL TPO, and 40 ng/mL Flt-
3L. Cells were passed every 4-5 days.  
Colony forming unit assays 
Individual colony assays were conducted with 50,000 input cells and plated in 
M3434 (StemCell Technologies) on 35mm dishes. Primitive erythroid colonies 
were counted after 6 days, all other colonies counted at day 10.  
FACS analysis and cell purification 
Flow analysis was performed on BD Fortessa. Fluorescence-activated cell 
sorting was performed using FACSAria. All antibodies were from eBioscience 
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unless otherwise noted. Embryoid body and stroma co-cultures were stained with 
c-Kit-APC (2B8), CD41-PacBlue (Mwreg-30), CD45-APC eFluor780 (30-F11), 
Tie2-PE (Tek4), Cd11b- APC eFluor780 (M1/70)and CD150-PE (mShad). Flk1+ 
cells were enriched using Flk1-APC (Avas12a1), and purified with Anti-APC 
microbeads (Miltenyi) according to manufacturer recommendations.  
Quantitative RT-PCR 
  RNA was isolated using the RNeasy Plus Micro kit (Qiagen). First-strand 
cDNA synthesis was performed using the Superscript VILO cDNA Synthesis kit 
(Invitrogen). Runx1 isoform specific RT-qPCR was performed using Platinum 
SYBR Green qPCR Supermix (Invitrogen), and normalized to GAPDH. Primers 
used for isoform specific RT-PCR were described previously113. All other 
expression analyses were performed using Taqman gene expression assays, 
and the following probe sets: Runx1  Mm01213404_m1, Gata1 
Mm01352636_m1, Gata2 Mm00492301_m1, Gata3 Mm00484683_m1, PU.1 
Mm03048233_m1, SCL Mm01187033_m1. 
Bioluminescence imaging 
Bioluminescent imaging was conducted using  the Xenogen IVIS imaging system 
(Caliper Life Sciences, Hopkinton, MA) according to manufacturer instructions. 
Data are presented as total flux.  
Statistics 
Statistical analysis was performed using a Student t test, with P value less 
than 0.05 considered significant. 
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Results 
Inducible cassette exchange allows rapid generation of targeted, single 
copy Runx1 reporter mESC lines 
 The activity of randomly integrated tissue-specific reporter constructs is 
influenced by both copy-number and the chromatin structure of their integration 
site, making the unbiased interrogation of regulatory element function difficult. As 
previous studies have shown that tissue-specific regulatory elements retain their 
fidelity when targeted to the ubiquitously expressed Hprt locus, we reasoned that 
this setting would allow unbiased examination of Runx1 regulatory element 
activity during in vitro differentiation of mESC152-154.  To test this hypothesis, we 
generated reporter constructs in which GFP is under the transcriptional control of 
the P1 or P2 promoters alone, or in combination with the +23 enhancer region99 
(Figure 1 A). To overcome the relatively low efficiency of homology based 
targeting, we used a previously described mESC line in which the Hprt locus can 
be targeted with high efficiency via cre/lox mediated inducible cassette exchange 
(ICE)119.  Using the ICE system, we were able to rapidly generate a panel of 
clonal mESC lines harboring single copies of our reporter constructs at the Hprt 
locus (Figure 1 B).  
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Figure 1.  
 
Figure 1. Construct design and Hprt targeting in mESC 
(A) Construct design and cre/lox recombination mediated targeting to the Hprt 
locus. In the presence of cre, p2Lox cassette replaces cre ORF at Hprt and 
places a PGK promoter and ATG upstream of neomycin resistance gene. (B) 
PCR based genotyping analysis of clonal mESC lines after selection and 
expansion.  
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Hematopoietic specificity of Runx1 reporter constructs during in vitro 
differentiation of mESC 
 To assess the hematopoietic specificity of Runx1 regulatory elements in 
our mESC lines, we differentiated them as EB and performed flow cytometry 
based analysis of GFP expression at day 6, when hematopoietic progenitor 
activity becomes readily detectable155 (Figure 2 A). As CD41 is the earliest 
marker of the hematopoietic lineage during mouse development, we examined 
the co-expression of GFP and CD41127.  In contrast to previous reports, we find 
that both the P1 and P2 promoters alone are sufficient to enrich GFP expression 
in CD41+ hematopoietic cells (Figure 2 B). Consistent with previous studies, we 
show that the +23 element is sufficient to promote hematopoietic specific 
transcription, and increases both the intensity and specificity of hematopoietic 
transcription from the P1 and P2 promoters (Figure 2 C).  Runx1 P2 expression 
is specifically required in Tie2+ hemogenic endothelial cells for their subsequent 
transition to P1+ definitive hematopoietic cells103.  To determine whether our 
individual reporter constructs reflected this pattern, we examined the co-
expression of GFP and Tie2 in day 6 EB. As expected, the P2 and P2/+23 EBs 
have the highest percentage of Tie2+GFP+ cells (Figure 2 D). When compared 
to P2 and P2/+23, we find that a higher proportion of Tie2+GFP+ cells in the +23, 
P1, and P1/+23 EBs co-express CD41, suggesting that the transcriptional activity 
of these constructs reflects either a subset of HE undergoing endothelial-
hematopoietic transition (EHT), or post-EHT hematopoietic cells that have not yet 
lost Tie2.  
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To test these two scenarios, we placed day 4 P1/+23 EB derived Flk1+ 
cells in two-dimensional culture and examined HE clusters for the expression of 
GFP and CD41 by fluorescence microscopy.  We find that GFP+ cells are 
present in morphologically distinct clusters of adherent and non-adherent cells 
and that these cells co-express CD41 (Figure 2 F). This pattern of labeling 
adherent and non-adherent cells is also observed when day 4 Flk1+ cells are co-
cultured with hematopoietic supportive OP9 stromal cells (Supplementary Figure 
1 A). Based on these observations, we conclude that the P1/+23 construct labels 
CD41+ HE prior to the completion of EHT, and that this labeling continues in 
post-EHT hematopoietic cells.  
Altogether, these data demonstrate that ICE mediated Hprt targeting 
allows rapid, unbiased examination of Runx1 regulatory element activity during in 
vitro differentiation of mESC.  All elements drive hematopoietic specific labeling, 
though subtle differences are observed between constructs. In particular, the P2 
promoter appears to restrain +23 enhancer activity to CD41- HE, while the P1 
promoter reinforces +23 activity in CD41+ cells emerging from HE. That the 
P1/+23 construct specifically labels emerging hematopoietic cells with high 
specificity suggests it may be optimal to screen for conditions that promote the 
emergence of Runx1+ hematopoietic cells during in vitro differentiation of mESC. 
Indeed, this construct reflects endogenous Runx1 expression with high fidelity 
(Supplemental Figure 1 B). 
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Figure 2 
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Figure 2. Activity of Runx1 reporter constructs in day 6 embryoid bodies. 
(A) Embryoid body differentiation of reporter mESC. (B) FACS analysis of 
CD41 and GFP expression in P1 and P2 reporter EBs at day 6. (C) FACS 
analysis of CD41 and GFP expression in +23, P1/+23, and P2/+23 reporter 
EBs at day 6. (D) FACS analysis of Tie2 and GFP expression in reporter EBs 
at day 6. (E) FACS analysis of CD41 expression within the Tie2+GFP+ 
population of reporter EBs at day 6. (F) Fluorescence microscopy images of 
CD41 (red) and GFP (green) localization in adherent HE clusters formed 
during two-dimensional culture of day 4 EB Flk1+ cells. 
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Runx1 dual-promoter reporter constructs allow simultaneous monitoring of 
distinct hematopoietic populations during in vitro differentiation of mESC 
The fact that the P1 and P2 promoters exhibit differential effects on the 
+23 enhancer suggested that these promoters may also exert contextual effects 
on each other.  To assess this possibility, we generated dual-fluorescent and 
bioluminescent reporter constructs containing the P1, +23, and P2 regulatory 
elements in their appropriate genomic order and targeted them to the Hprt locus 
in mESC (Figure 3 A).  To determine whether this context altered the activity of 
either promoter during differentiation, we performed FACS analysis of P1 driven 
GFP and P2 driven mCherry (Figure 3 A) expression over the course of EB 
differentiation. Consistent with previous reports of P2 derived Runx1b mRNA 
expression in mESC137, day 1 EBs contain a residual mCherry+GFP-  population 
that decreases rapidly and is virtually absent by day 3.  At day 5 mCherry+GFP- 
cells reappear and increase in frequency by day 6, at which point their 
percentage plateaus until decreasing between days 7 and 8. Interestingly, a 
small population of mCherry+GFP+ cells emerges at day 6 and increase in 
frequency until day 8, when a distinct mCherry+GFP+ population is evident 
(Figure 3 B). In day 6 EB, the mCherry+GFP- and mCherry+GFP+ populations 
contain a higher frequency of CD41+ cells than the mCherry-GFP- population, 
however the highest level of CD41+ enrichment is observed in the mCherry+ 
GFP+ population. Consistent with our single-promoter findings, mCherry+GFP-
Tie2+ cells are preferentially CD41-, whereas mCherry+GFP+Tie2+ cells are 
preferentially CD41+ (Figure 3 C). Additionally, we find that the mCherry+GFP+ 
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subpopulation is highly enriched in cKit+CD41+ progenitors at day 6 compared to 
both the mCherry-GFP- and mCherry+GFP- fractions (Figure 3 D). Thus, while 
similarities exist between the activities of the P1 and P2 promoters in our single- 
and dual-promoter constructs, there are also notable differences; namely, P1-
GFP+ cells are generally less frequent in the dual-promoter EBs at day 6, while 
their enrichment of CD41+ cells is higher. Taken together, these data 
demonstrate that the inclusion of all elements in cis results in the dynamic 
temporal labeling of phenotypically distinct cell populations during in vitro 
differentiation of mESC.  
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Figure 3 
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Figure 3. Dual-promoter reporter constructs and activity of dual-fluorescent 
construct during embryoid body differentiation 
(A) Diagram of Runx1 dual-reporter constructs targeted to Hprt. (B) FACS 
analysis of mCherry and GFP expressing populations over the time-course of 
EB differentiation. (C) Fluorescence activated cell sorting (FACS) analysis of 
Tie2 and CD41 expression within the mCherry/GFP sub-populations in day 6 
EB. (D) FACS analysis of cKit and CD41 expression within mCherry/GFP 
sub-populations in day 6 EB.  
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Dual-promoter reporter constructs accurately reflect endogenous Runx1 
differential promoter usage 
 The distinct temporal and cell-type specific activities of the Runx1 
promoters in our dual-fluorescent construct resembled previous descriptions of 
endogenous Runx1 promoter switching during development 101-103,113. We thus 
wondered whether the dynamic reporter expression pattern observed during 
differentiation of our reporter mESC lines accurately reflected endogenous 
Runx1 promoter usage. To address this question, we FACS purified the 
mCherry-GFP-, mCherry+GFP-, and mCherry+GFP+ sub-populations from day 8 
EB (Figure 4 A), and examined the levels of endogenous P1 and P2 derived 
mRNA isoforms in each population by reverse-transcription quantitative 
polymerase chain reaction (RT-qPCR). Both the mCherry-GFP+ and 
mCherry+GFP+ populations express higher levels of the P1 and P2 isoforms 
than mCherry-GFP- cells, however P1 derived mRNA levels are ~4-fold higher in 
mCherry+GFP+ versus mCherry+GFP- cells (Figure 4 B). Because it is not 
possible to prospectively FACS enrich the equivalent populations from our dual-
bioluminescent reporter line, we instead compared the levels of P1-Renilla and 
P2-Firelfy luciferases in day 5 EBs to that of day 6 EB, as this time-point 
represented the first appearance of P1+ cells in our dual-fluorescent reporter 
experiments. We find that the levels of both P2-Firefly and P1-Renilla are higher 
in day 6 versus day 5 EB, which reflects endogenous Runx1 mRNA isoform 
levels in both temporal specificity and magnitude (Figure 4 C, D).   
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Figure 4 
 
 
 
 
 
 
77 
 
Figure 4. Relationship of endogenous Runx1 mRNA isoforms and dual-
reporter construct activity.  
(A) Fluorescence activated cell sorting (FACS) based purification of 
mCherry/GFP sub-populations from dual-fluorescent reporter EBs at day 8. 
(B) RT-qPCR analysis of Runx1 isoform expression in FACS purified 
mCherry-GFP-  (M-G-), mCherry+GFP- (M+G-), and mCherry+GFP+ (M+G+) 
subpopulations in day 8 EB. (D)  P1-Renilla and P2-Firefly activity and RT-
qPCR analysis of Runx1 isoform expression in day 5 and 6 dual-
bioluminescent EB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
The mCherry+GFP+ population is enriched with definitive hematopoietic 
potential in day 8 embryoid bodies 
 The establishment of defined mCherry/GFP subpopulations in day 8 EB 
(Figure 5 A), suggested that these populations may represent cell types with 
distinct hematopoietic potential. To investigate this further, we first assessed the 
surface antigen profile of these subpopulations in day 8 EB. Pan hematopoietic 
labeling by CD41 in the early embryo is gradually replaced by CD45 beginning at 
the time of definitive hematopoietic formation in the AGM, and remains the 
predominant marker of the hematopoietic lineage into the adult 47,156.  This 
pattern is reflected in EB, where CD45+ cells are not readily detectable until day 
7, which lead us to wonder whether the mCherry/GFP subpopulations at day 8 
exhibited differential expression of CD41 and CD45.  As expected based on our 
previous results, the mCherry+GFP- and mCherry+GFP+ populations contain 
higher proportions of CD41+ cells than the mCherry-GFP- population. A subset 
of CD41+ cells co-express CD45 in both mCherry+GFP- and mCherry+GFP+ 
populations, however the mCherry+GFP+ fraction contains a dramatically higher 
proportion of CD41+CD45+ cells (Figure 5 B). Furthermore, it appears that as 
CD45 expression increases, CD41 expression begins to decrease, suggesting 
that these cells are transitioning toward a definitive CD41-CD45+ phenotype. To 
assess the progenitor content of the hematopoietic fractions, we examined the 
co-expression of cKit in the CD41 and CD45 populations. Similar to our day 6 
results, the mCherry+GFP+ population contained the majority of cKit+CD41+ and 
cKit+CD45+ cells (Figure 5 C), with a greater proportion of cKit+CD41+ cells co-
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expressing CD45 in the mCherry+GFP+ fraction (Figure 5 D).  It was previously 
reported that mESC derived HSC derived via the enforced expression of Cdx4 
and HoxB4 express the HSC specific SLAM family antigen CD150 157. Upon 
examining the expression of CD150 within the mCherry/GFP subpopulations, we 
found the mCherry+GFP+ population to contain the highest frequency of CD150+ 
cells, further suggesting that this fraction contains a population enriched with 
definitive hematopoietic potential (Figure 5 F).  
 The distinct surface antigen profiles of each subpopulation suggested that 
there may also exhibit distinct molecular profiles. To examine this possibility, we 
examined the expression levels of key hematopoietic transcription factors in each 
subpopulation by RT-qPCR. GATA family members 1-3 play distinct roles during 
hematopoietic development; Gata3 expression in non-hematopoietic cells of the 
AGM promotes HSC formation158, while both Gata1 and Gata2 are cell intrinsic 
regulators of hematopoietic cell development64,76,159. Reflecting this, we find that 
the predominantly non-hematopoietic mCherry-GFP- population expresses the 
highest levels of Gata3, and while both Gata1 and Gata2 mRNA levels are higher 
in the mCherry+GFP- and mCherry+GFP+ populations, Gata2 expression is 
specifically enriched in the mCherry+GFP+ fraction (Figure 5 G). The 
transcription factor SCL, which is required for hemangioblast formation, is 
enriched within the mCherry+GFP- and mCherry+GFP+ fractions, as is the 
transcription factor PU.1, which is critically required for the formation of definitive 
HSC and is a direct target of Runx1; interestingly, PU.1 expression is highest 
within the mCherry+GFP+ population (Figure 5 H). Taken together, the surface 
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antigen profiles and gene expression signatures show that the mCherry/GFP 
sub-fractions represent phenotypically distinct cell populations. Both the 
mCherry+GFP- and mCherry+GFP+ populations are enriched with hematopoietic 
cells; however our data suggest that definitive hematopoietic cells are specifically 
contained with mCherry+GFP+ population.  
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Figure 5 A-D 
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Figure 5 E-G 
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Figure 5. Phenotypic and molecular analysis of mCherry/GFP 
subpopulations in day 8 EB.  
(A) FACS analysis of mCherry and GFP expression showing the gating 
strategy used in subsequent analysis.  (B) FACS analysis of CD41 and CD45 
expression within mCherry/GFP subfractions. (C) FACS analysis of cKit/CD41 
and cKit/CD45 expression within mCherry/GFP subfractions. (D) Co-
expression of CD45 in the cKit+CD41+ subfraction of the mCherry+GFP- and 
mCherry+GFP+ populations. (E) FACS analysis of CD150 expression within 
the mCherry/GFP subfractions. (F) RT-qPCR analysis of Gata1, Gata2, and 
Gata3 mRNA expression in the mCherry-GFP- (M-G-), mCherry+GFP- (M+G-
), and mCherry+GFP+ (M+G+) subfractions. (G) RT-qPCR analysis of Scl 
and Pu.1 mRNA expression in mCherry-GFP- (M-G-), mCherry+GFP- (M+G-
), and mCherry+GFP+ (M+G+) subfractions. 
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Multi-lineage and definitive erythroid colony forming unit activity resides 
within the mCherry+GFP+ population 
 Our phenotypic and molecular analyses suggested that the 
mCherry+GFP+ population is highly enriched with definitive hematopoietic 
progenitors.  To determine whether this was true at a functional level, we 
performed methylcellulose based colony forming unit (CFU) assays with the 
individual mCherry/GFP subpopulations from day 8 EB. Consistent with our 
phenotypic analysis, virtually all multilineage CFU activity is restricted to the 
mCherry+GFP+ subfraction (Figure 6 A). While the mCherry+GFP- and 
mCherry+GFP+ populations contain similar numbers of early forming primitive 
erythroid CFU (EryP), later-developing definitive erythroid CFU (EryD) are 
restricted to the mCherry+GFP+ subfraction (Figure 6 B). These data confirm our 
phenotype based results, and conclusively demonstrate that definitive 
hematopoietic progenitor activity is restricted to the mCherry+GFP+ subfraction 
in day 8 EB.   
 
 
 
 
 
 
 
 
85 
 
Figure 6 
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Figure 6. Colony forming unit activity in day 8 EB mCherry/GFP 
subfractions.  
(A) Qualitative and quantitative analysis of CFU activity in day 8 EB mCherry-
GFP- (M-G-), mCherry+GFP- (M+G-), and mCherry+GFP+ (M+G+) 
subfractions. CFU-M (macrophage), CFU-GM (granulocyte-macrophage), 
CFU-GEMM (granulocyte-erythrocyte-macrophage-megakaryocyte)  (B) 
Quantitative analysis of erythroid CFU activity in day 8 EB mCherry-GFP- (M-
G-), mCherry+GFP- (M+G-), and mCherry+GFP+ (M+G+) subfractions. EryP 
(primitive erythroid), EryD (definitive erythroid).  
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Differential effects of hematopoietic stroma and cytokine combinations on 
the expansion of day 8 EB derived mCherry+GFP+ cells 
 We next sought to identify preliminary culture conditions that were capable 
of expanding day 8 EB mCherry+GFP+ derived hematopoietic progenitors. As 
stromal cells derived from hematopoietic organs have shown utility for this 
purpose, we tested the capacity of bone marrow derived OP9, and AGM region 
derived AM20.1B4 and UG26.1B6 stromal lines to expand mCherry+GFP+ 
progenitors, since these lines have shown the ability to expand and/or support 
hematopoietic differentiation and expansion from embryonic stem cells83,151,160.  
Since OP9 co-culture coupled with Flt3L, TPO, SCF, and VEGF promotes the 
efficient expansion of mESC-HSC derived via the overexpression of HOXB4, we 
used this as our baseline for comparison87. Both IL-3 and IL-6 have been shown 
to promote the formation of embryonic HSC and/or enhance the expansion and 
maintenance of adult HSC ex vivo; therefore we assessed the effect of adding IL-
3, or IL-3 and IL-6 to FTSV supplemented stromal co-cultures 93,161,162.  Day 8 EB 
mCherry+GFP+ were FACS purified and 3.0 x 104 viable cells were plated onto 
sub-confluent stroma and cultured for an additional 6 days (D8+6) before 
analysis. In general, dual-positivity was retained most effectively by the AGM 
stromal lines, whereas a fraction of mCherry+GFP- cells was present within the 
OP9 co-cultures at D8+6. Neither IL-3 or IL-6 had a substantial effect in the AGM 
lines, however IL-3 appears to promote the retention of mCherry+GFP+ cells on 
OP9 (Figure 7 A). Bead-enhanced FACS quantification of absolute cell numbers 
in D8+6 co-cultures found that, in general, the AGM lines are more effective at 
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expanding mCherry+GFP+ cells than OP9, with the AM20.1B4 line appearing to 
be most effective (Figure 7 B). The expanding hematopoietic cell populations are 
morphologically diverse (Supplemental Figure 2 A, B), and predominantly of the 
myeloid lineage as evidenced by the expression of CD11b (Figure 7 C); 
particularly in the AGM lines, which unlike OP9, contain a functional M-CSF 
gene. While this could be interpreted as a higher frequency of differentiation, it is 
worth noting that definitive HSC in the fetal liver express CD11b121.  Nonetheless, 
compared to OP9, the AGM stromal lines maintain the highest percentage of 
cKit+CD45+ hematopoietic progenitors, and addition of IL-3 and IL-3/IL-6 to the 
AGM co-cultures does not substantially alter this capacity; however, IL-3 does 
appear to slightly enhance the retention of cKit+CD45+ cells in the OP9 co-
cultures (Figure 7 D). Collectively, these data suggest that the microenvironment 
present within AGM co-cultures is most conducive to the expansion of both 
mCherry+GFP+ and cKit+CD45+ cells from day 8 EB. The fact that IL-3 
enhances the supportive effects of OP9 but not AGM stroma suggests that OP9 
may produce suboptimal levels of endogenous IL-3 compared to the AGM lines, 
which is consistent with the known production of IL-3 by AGM stroma in vivo 161.   
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Figure 7 
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Figure 7. Stromal co-culture of mCherry+GFP+ cells from day 8 EB.  
(A) FACS analysis of mCherry and GFP expression in D8+6 stromal co-
cultures. (B) Total number of mCherry+GFP+ cells in D8+6 stromal co-
cultures as determined by bead-enhanced flow cytometry. (C) FACS analysis 
of CD11b expression in D8+6 stromal co-cultures. (D) FACS analysis of cKit 
and CD45 expression in D8+6 stromal co-cultures.   
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Dual-bioluminescent reporter construct allows non-invasive monitoring of 
Runx1 expression during in vitro differentiation  
 While the dual-fluorescent reporter mESC line allows the prospective 
isolation and characterization of promoter specific sub-populations during 
differentiation, quantitative analysis generally requires culture disruption and 
modest numbers of cells for analysis, which can be problematic for screening 
large numbers of small scale cultures. In addition, analysis of promoter 
expression levels by fluorescent protein intensity is generally less sensitive than 
that afforded by bioluminescence.  We previously demonstrated that our dual-
bioluminescent reporter construct accurately reflected Runx1 promoter switching 
during EB differentiation (Figure 4 C). To determine whether this reporter could 
be used to analyze the emergence of P2+ hemogenic endothelium in small scale 
cultures amenable to high-throughput screening, we plated day 4 EB derived 
Flk1+ cells in 48-well culture dishes containing basal IMDM, IMDM+FTSV, 
endothelial supportive EGM2, or EGM2+FTSV, and assessed the activity of P1-
Renilla and P2-Firelfy after 48hrs in culture. As expected, P1-Renilla activity did 
not reach detectable levels in any condition; however P2-Firefly activity was 
detected in all conditions (Figure 8 A). The highest level of P2-Firefly activity was 
observed with EGM2, suggesting that this media is superior to IMDM in its ability 
to promote P2+ activity (Figure 8 B). Importantly, this experiment demonstrates 
that the dual-bioluminescent reporter is suitable for non-invasive analysis of 
Runx1 expression within small scale cultures, making it suitable for high-
throughput analysis. 
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 Next, we sought to determine whether the dual-bioluminescent reporter 
was able reflect changes in Runx1 promoter activity within committed 
hematopoietic progenitors. The distal isoform of Runx1 is highly expressed in 
developing thymocytes, suggesting that signaling pathways promoting the 
development of T-cells may also regulate the activity of the P1 promoter 106.  
Induction of the T-cell lineage from mESC derived hematopoietic progenitors is 
promoted via co-culture with OP9 engineered to over express the Notch ligand, 
Delta-like 1163. As Runx1-Notch interactions have been previously described 164, 
we wondered whether Notch signaling in OP9-DL1 co-cultures would alter 
promoter activity in our dual bio-luminescent reporter system.  To test this, we 
first generated definitive hematopoietic progenitors from our dual-bioluminescent 
mESC via HOXB4 overexpression as previously described87. After an initial 
phase of maturation and expansion on OP9, we passaged the HOXB4 
overexpressing hematopoietic progenitors onto either OP9 or OP9-DL1 stroma 
and assessed the levels of P1-Renilla and P2-Firefly activity after 5 days (Figure 
8 C). Consistent with our previous findings, P1 activity was detected in HOXB4 
overexpressing cells on OP9, however co-culture on OP9-DL1 resulted in a 
significant increase in the level of P1-Renilla activity and a decrease in the 
activity of P2-Firelfy, suggesting that Notch signaling increases Runx1 P1 
expression (Figure 8 D). This effect was also mirrored by mRNA isoform 
expression, showing that our dual-bioluminescent reporter construct accurately 
reflects endogenous Runx1 promoter activity (Figure 8 E). Taken together, these 
data demonstrate that our dual-bioluminescent reporter system allows the non-
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invasive monitoring of Runx1 promoter activity in committed hematopoietic  
progenitors; thereby allowing the identification of signaling pathways that 
modulate their respective activities.  
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Figure 8 
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Figure 8. Non-invasive monitoring of Runx1 promoter activity with dual-
bioluminescent reporter mESC 
(A) Bio-luminescent imaging of P1-Renilla and P2-Firefly activity in small 
scale two-dimensional cultures of EB derived Flk1+ mesoderm. (B) 
Quantification of P2-Firefly bio-luminescence activity in different culture 
media. (C) Bio-luminescent imaging of P1-Renilla and P2-Firefly activity in 
HOXB4 overexpressing hematopoietic progenitors cultured on OP9 and OP9-
DL1. (D) Quantification of bio-luminescence in HOXB4 overexpressing 
hematopoietic progenitors cultured on OP9 and OP9-DL1. (E) RT-qPCR 
analysis of Runx1 mRNA isoforms in HOXB4 overexpressing hematopoietic 
progenitors cultured on OP9 and OP9-DL1. Data represent two independent 
experiments assayed in triplicate.  *p<0.05.  
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Discussion 
 Runx1 is a critical regulator of both embryonic and adult hematopoiesis, 
and is frequently dis-regulated in hematopoietic malignancy; thus its regulation is 
an area of intense investigation108,109,145,148.  Runx1 transcription initiates from 
two spatially distant and differentially regulated promoters, and its hematopoietic 
activity is influenced by the presence of an intronic enhancer (+23) 98-102,106. 
Interestingly, proximal (P2) promoter activity gives way to distal (P1) promoter 
driven expression at the onset of definitive hematopoiesis, suggesting that 
promoter specific reporters may assist efforts to derive definitive HSC from 
pluripotent stem cells (PSC).  However, both promoters failed to drive 
hematopoietic specific reporting in transgenic animals and plasmid based 
reporter assays99,100.  Reporter constructs targeted to the endogenous promoters  
accurately reflect their activity103, but this method is time-consuming and not 
conducive to combinatorial or mutation based investigation of important 
regulatory sequences.  Knock-in also results in Runx1 haploinsufficiency, which 
is known to have biological consequences148,149.  In the present study, we have 
demonstrated that targeting of minimal Runx1 reporter constructs to the 
transgene permissive152-154 Hprt locus in mESC via ICE recombination allows the 
unbiased interrogation of regulatory element function during in vitro 
hematopoietic differentiation. In contrast to previous reports, we show that the P1 
and P2 promoters are capable of directing hematopoietic specific labeling. This 
discrepancy could be the result of position and/or copy number effects 
associated with randomly integrated transgenes and episomal plasmid 
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constructs, which may generate enough background signal to preclude the 
reliable detection of low level specificity.  As ICE mediated recombination 
replaces a doxycyclin inducible Cre-recombinase ORF, it is possible that the 
basal activity of the individual promoter elements is enhanced by the presence of 
the TRE element, however any effect is likely to be minimal since the activity of 
this element in the absence of doxycyclin is extremely low, and cannot explain 
the hematopoietic specific expression.  Nonetheless, this issue can be avoided if 
necessary by simply reversing the orientation of the reporter construct in future 
experiments. While the hematopoietic specificity of the individual  promoter 
elements differed from previous observations, their specific temporal activities 
reflected previous observations in that the P2 promoter preferentially labeled 
CD41-Tie2+ HE, while the P1 promoter was biased toward CD41+Tie2+ HE and 
fully committed Tie2-CD41+ hematopoietic cells103. As expected, the +23 
element enhanced the activity of both promoters; however its enhancing capacity 
appears to be influenced by the regulative capacity of the respective promoter 
elements in our P1/+23 and P2/+23 constructs, suggesting that the individual 
elements exert contextual effects on one another. Taken together, these data 
demonstrate that the Hprt locus is permissive to maintaining the activity of 
exogenous Runx1 regulatory elements, allowing direct comparison of their 
individual activities during in vitro hematopoietic differentiation of mESC. 
Replacing homology-based targeting with the ICE system dramatically enhances 
Hprt targeting in mESC 119,165, making it possible to rapidly generate clonal 
mESC lines harboring single copy reporter constructs. We exploited these 
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properties to further refine the current understanding of previously defined Runx1 
regulatory elements. Future studies with different regions of each regulatory 
element, novel elements, or elements containing mutations in suspected 
transcription factor binding sites will further refine our understanding of Runx1 
regulation.  
As our primary interest was to identify novel signatures of definitive 
hematopoiesis that could be used to optimize in vitro differentiation of mESC, we 
were primarily interested in replicating the definitive specific activity of the P1 
promoter. While differences between the activities of the P1 and P2 promoters in 
our single reporter constructs suggested that they retained some of their inherent 
specificity in isolation, several observations suggested that neither the P1 or 
P1/+23 constructs optimally reflected P1 activity. First, our P1 and P1/+23 
constructs labeled a considerably higher percentage of cells in day 6 EB than the 
knock-in results reported by Sroczynska et al103. Second, the fact that the P1 and 
P2 promoters differentially impacted the activity of the +23 enhancer suggested 
that they may also impact the activity of one another; a theory that is supported 
by the fact that the two promoters share binding sites for hematopoietic 
transcription factors, including Runx1100. Furthermore, the fact that the promoter 
specific mRNA isoforms exhibit differential methods of translation suggests that 
protein production from each may differ under specific physiological 
conditions105.  Indeed, our dual-reporter constructs show that the inclusion of all 
three regulatory elements in their appropriate genomic order further specifies P1 
and P2 driven reporter activity, and is sufficient to reflect endogenous Runx1 
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promoter switching during in vitro differentiation of mESC. The dual-fluorescent 
reporter allowed us to prospectively isolate and characterize the individual 
promoter-specific cell populations, which we exploited to demonstrate that 
definitive hematopoietic progenitor activity is preferentially contained within the 
P1 expressing mCherry+GFP+ subpopulation in day 8 EB. This mirrors what was 
observed in the knock-in reporter line103, suggesting that our constructs not only 
reflect the expression profile of the individual promoters, but also the functional 
capacity of the cell populations in which they are active.  We then demonstrated 
that compared to bone marrow derived OP9, AGM region derived AM20.1B4 and 
UG26.1B6 stromal lines are most effective at maintaining  hematopoietic 
progenitors contained within the mCherry+GFP+  population. This is not 
particularly surprising considering that the AGM region gives rise to FL and  adult 
HSC; both of which preferentially express the P1 mRNA isoform113.  Neither IL-3 
nor IL-3/IL-6 promoted the supportive capacity of the AGM stroma; however IL-3 
did enhance the supportive capacity of OP9, suggesting that this line may 
produce suboptimal levels of this molecule.  The lack of a functional M-CSF gene 
in OP9 reduces the overproduction of macrophages common in other stromal 
lines, allowing more effective generation of multiple hematopoietic lineages; thus 
it is plausible that if supplemented with IL-3 and possibly other factors present in 
the AGM lines, OP9 may in fact prove a more effective system for the generation 
of diverse hematopoietic lineages from the mCherry+GFP+ population. 
Conversely, the emergence of TALEN166 and CRISPR167 as highly efficient tools 
for gene modification should make it feasible to produce M-CSF null AGM lines.  
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While we focused on the generation of mCherry+GFP+ hematopoietic cells in 
EB, our reporter constructs should be equally useful in other systems. It would be 
particularly interesting to compare EB based differentiation to the stroma-only 
methods reported by others 83,160. Fully defined differentiation strategies are 
desirable for future clinical application. Our preliminary experiments in serum-free 
defined cultures91 have found that our system functions appropriately in this 
setting, and is thus a novel tool with which to refine current systems.  
Systems amenable to high-throughput screening have allowed the 
identification of novel modulators of hematopoietic development12.  In general, 
highly sensitive readouts that do not require laborious sample processing steps 
are best suited for high-throughput screens.  We have demonstrated that our 
dual-bioluminescent reporter construct fulfills these criteria. In our small scale 
analysis, we demonstrated that the commercially available EGM2 media allows 
efficient generation of Runx1-P2+ hematopoietic precursors from Flk1+ 
mesoderm, making it a suitable baseline for further analysis of cytokines or small 
molecules that enhance this process.  As the bio-luminescent readout does not 
require cell disruption and is sensitive enough to be readily detected in small 
scale cultures, our dual-bioluminescent reporter provides a novel platform for 
future high-throughput screening of hematopoietic specification during in vitro 
differentiation. Runx1 promoter isoforms play specific roles during lineage 
commitment in the adult hematopoietic system107,168,169.  We used our dual-
fluorescent reporter line and OP9-DL1 co-culture to demonstrate that Notch 
signaling promotes P1 activity in mESC derived hematopoietic progenitors 
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overexpressing HOXB4.  This finding is consistent with the observations that 
developing thymocytes express high levels of P1-Runx1106, and that the OP9-
DL1 system preferentially drives T lineage specification163.  Taken together, 
these data demonstrate the dual-bioluminescent reporter is ideally suited for 
high-throughput screening of conditions that alter Runx1 promoter activity; 
whether it is during the initial specification of the hematopoietic lineage, or during 
differentiation of fully committed hematopoietic progenitors.  
Collectively, we have utilized Hprt targeting to conduct an unbiased 
combinatorial analysis of Runx1 regulatory element function during mESC 
differentiation. Our dual-reporter mESC lines accurately reflect promoter usage 
and provide novel tools for the identification of conditions that promote definitive 
hematopoiesis from PSC. As our constructs are relatively small (~3kb), and  
contain all elements in cis, they can be easily transferred to other cell lines, 
including pre-existing knock-out mESC lines and disease model iPSC. Since the 
structure and function of the human Runx1 locus is highly conserved between 
mouse and human, it is not unreasonable to suggest that reporters containing the 
minimal human regulatory elements may also accurately reflect promoter 
switching.   
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Supplementary Figure 1 
 
 
Supplemental Figure 1. P1/+23 reporter activity 
(A) GFP expressing cells in OP9 co-cultures from P1/+23 mESC line. (B) RT-
qPCR analysis of Runx1 expression in GFP- and GFP+ cells sorted from day 
6 P1/+23 EB.  
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Supplemental Figure 2 
 
 
 
 
104 
 
Supplemental Figure 2. Morphology of cells during stromal co-culture 
(A). Light microscope images of hematopoietic cells on AGM and OP9 stroma 
at 100x magnification. (B) Representative Romonowsky stained cytospins 
from AGM and OP9 stromal co-cultures.  
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Chapter 4 
Concluding Statements and Future Applications 
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 Pluripotent stem cells have the potential to revolutionize the field of 
regenerative medicine; however in order to achieve this reality, safe and efficient 
methods for their directed differentiation must be developed.  In general, these 
efforts rely on basic developmental research to provide information that can be 
applied to guide differentiation and subsequent characterization of terminal cell 
types. The current work focused primarily on hematopoietic differentiation of 
mESC, specifically the formation of the definitive wave of hematopoiesis that 
produces adult HSC.  Toward this end, we undertook both discovery (Chapter 2) 
and application (Chapter 3) based efforts to develop novel signatures of definitive 
hematopoiesis.  
 Hematopoietic differentiation of ESC was demonstrated shortly after their 
discovery20,77, and the large repertoire of hematopoietic cytokines accumulated 
over several decades of hematological research fostered the subsequent 
derivation of many terminal hematopoietic lineages from PSC14; however the 
derivation of HSC capable of long-term multilineage engraftment has not been 
reported. This is somewhat puzzling considering the accepted models of 
hematopoietic hierarchy in the adult, where HSC generate all mature 
hematopoietic lineages.  This is likely due to the fact that ESC derived 
hematopoiesis most closely resembles primitive hematopoiesis of the yolk-sac, 
which does not appear to produce the precursors of adult HSC36,38. At present, 
functional assays remain the most effective way to distinguish definitive from 
primitive hematopoiesis; however these assays are inherently retrospective and 
often laborious, particularly in the case of long-term engraftment assays.  
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Phenotypic signatures that distinguish primitive and definitive hematopoiesis 
would make it easier to identify conditions that promote definitive hematopoiesis 
during in vitro differentiation. 
 It was previously known that Runx1 expression is specifically required for 
definitive blood145, and that its expression switches from a proximal to a distal 
promoter at the time when definitive hematopoietic cells emerge in the embryo101-
103,112,113, however the mechanisms underlying this promoter switch were unclear. 
In Chapter 2, we describe a series of experiments exploring epigenetic changes 
at the Runx1 locus during hematopoietic development in vivo, and during mESC 
differentiation in vivo. As is typical with CpG rich promoter elements, we found 
that the core, P2 Runx1 promoter is remarkably unmethylated regardless of 
lineage or developmental status, a finding that is reflective of its broad 
expression pattern. Conversely, we found that the hematopoietic specific +23 
enhancer element is almost completely methylated in pluripotent mESC and in 
non-hematopoietic cells, but undergoes a dramatic loss of methylation upon 
hematopoietic commitment.  Of particular interest to the goal of deriving definitive 
HSC from ESC, the distal P1 Runx1 promoter element exhibits a loss of 
methylation that correlates with the transition to definitive HSC in vivo. Perhaps 
not surprisingly then, the P1 promoter is methylated in mESC derived 
hematopoietic progenitors, and remains methylated even after maturation toward 
a more definitive, albeit non-engrafting phenotype on adult bone marrow stroma.  
In order to confirm that our in vivo signature would be valid in mESC derived 
HSC, we exploited the unique capacity of HOXB4 to induce definitive HSC 
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formation from mESC87. Strikingly, we found that HOXB4 overexpression 
resulted in a loss of P1 methylation similar to that observed in vivo, and that this 
loss of methylation was reflected by a consequent increase in P1 mRNA. While 
this essentially confirmed that our in vivo epigenetic signature could be replicated 
during in vitro differentiation under the appropriate conditions, we took our 
findings a step further, and identified a direct role for HOXB4 in promoting the 
epigenetic remodeling of the P1 promoter.  DNA methylation patterns are 
relatively stable after their establishment, and are thought to solidify fate 
decisions during development 136. Thus, methylation based signatures like the 
one described here may be more robust indicators of lineage identity than gene 
expression, as exemplified by the use of DNA methylation patterns to confirm 
successful somatic cell reprogramming during iPSC generation. Considering the 
similarities between human and mouse developmental hematopoiesis, and the 
conservation of Runx1 structure and function between the two species, it is likely 
that this signature will apply to human PSC differentiation. The rapid 
advancement of next-generation sequencing technology and its application to 
methylation analysis should make it possible to rapidly assess the methylation 
profiles of hematopoietic progenitors derived from PSC under different 
conditions. Bisulfite sequencing is clonal in nature, but standard sequencing 
techniques are logistically limited to a relatively low number of reads. Next 
generation sequencing technologies should allow for the analysis of population 
wide distribution of methylation profiles, providing information on the 
homogeneity of the population being investigated.  
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To complement our discovery based approach, we used a previously 
described system for efficient targeting of DNA constructs the transgene 
permissive Hprt locus in mESC119,165 to perform an unbiased analysis of the 
activity of minimal Runx1 regulatory elements; both alone and in combination.  
Based on the information from the individual promoter constructs, we were able 
to develop dual-promoter constructs that accurately reflect Runx1 promoter 
switching; which to date had only been accomplished by targeting reporter genes 
to the endogenous Runx1 locus.  The dual-fluorescent line allowed us to monitor 
promoter activity during mESC differentiation, and facilitated the isolation of 
promoter specific subpopulations for further experiments.  We demonstrated that 
the P1 expressing population contains the majority of definitive hematopoietic 
activity in developing EB, and that the AGM microenvironment was most suited 
to their subsequent expansion. It will be interesting to use this system to further 
explore conditions that can produce a higher frequency of these cells during 
differentiation. As serum free fully defined culture systems are desirable, we have 
begun to explore the activity of our reporters in these conditions. In preliminary 
experiments, we have found that the dynamic activity of our reporter lines is 
maintained in serum-free fully defined culture conditons91.  Interestingly, around 
day 10 of EB differentiation in serum free cultures we have observed that a large 
portion of viable cells detach from the EB and remain viable in suspension. 
Surprisingly, these cells contain a high proportion of mCherry+GFP+ cells 
compared to the EB proper, and are enriched with colony forming cells (Figure 
1). It will be interesting to further explore this cell population.  
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Figure 1 
 
 
Figure 1. FACS analysis and CFU activity of EB and supernatant cell 
fractions at day 10.  
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We also created a dual-bioluminescent reporter construct that effectively 
reported Runx1 promoter activity. The high sensitivity of bio-luminescence 
compared to fluorescence based analysis provides certain advantages, 
particularly for the analysis of small scale cell cultures that are suited to high 
throughput analysis. We effectively demonstrated that our reporter construct 
allows the non-invasive detection of Runx1 promoter activity in small scale 
cultures of Flk1+ mesoderm, which allowed us to compare the effectiveness of 
several culture conditions to promote hematopoietic specification.  Furthermore, 
we showed that this reporter could also be used to assay the effects of certain 
signaling pathways on promoter activity in committed hematopoietic progenitors. 
In our example, we demonstrated that Notch signaling promotes that activity of 
the P1 promoter. Thus this system should be an excellent platform for high-
throughput screening of small molecules or cytokine combinations that promote 
hematopoietic development.  The dual-fluorescent reporter could also be useful 
to examine the behavior and localization of hematopoietic cells post-transplant. 
Indeed, we performed a pilot experiment in which we transplanted dual-
bioluminescent hematopoietic progenitors derived via HOXB4 overexpression 
and found that bioluminescent activity appears to accurately reflect the 
engraftment and localization of cells post-transplant (Figure 2 A), though we were 
only able to detect P2-Firelfy activity in this experiment, probably due to the poor 
tissue penetration of short-wavelength Renilla bioluminescence.  To overcome 
this issue, and the need to deliver two different substrates, we have created 
constructs that replace Renilla and Firefly with red and green spectra shifted 
112 
 
luciferase variants that are ideally suited for in vivo imaging, can be spectrally 
separated,  and metabolize a common substrate170. Furthermore, in an effort to 
combine the unique capabilities of the dual-fluorescent and dual-bioluminescent 
reporters, we have generated a construct in which the fluorescent and 
bioluminescent reporter cDNAs are linked by picornaviral-based 2A sequences171 
(Figure 2 B). These reporters should allow for future studies in which cells can be 
non-invasively monitored by bioluminescence, FACS purified at desired time-
points, and subsequently monitored after transplantation by bioluminescence. 
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Figure 2 
 
 
Figure 2. In vivo bioluminescence imaging and improved dual-
bioluminescent reporter constructs. 
(A) Bio-luminescent imaging of P2-Firefly activity 1 month post-transplant of 
HOXB4 overexpressing hematopoietic progenitors derived from dual-
bioluminescent reporter mESC. (B) Design of improved dual-bioluminescent 
and dual-bioluminescent/fluorescent constructs.  
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In summary, this work has provided new insight into the basic biological 
processes that regulate the formation of definitive HSC during development, and 
in doing so has identified a novel molecular signature of definitive hematopoiesis. 
The reporter constructs and mESC cell lines we have developed will be valuable 
tools for future efforts to improve their hematopoietic differentiation. In sum, the 
findings described in this dissertation move us one step closer to the ultimate 
goal of deriving transplantable HSC from pluripotent stem cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
Bibliography 
 
1. LORENZ E, UPHOFF D, REID TR, SHELTON E. Modification of irradiation injury in mice and 
guinea pigs by bone marrow injections. J Natl Cancer Inst. 1951;12(1):197-201. 
2. Hong R, Cooper MD, Allan MJ, Kay HE, Meuwissen H, Good RA. Immunological 
restitution in lymphopenic immunological deficiency syndrome. Lancet. 1968;1(7541):503-506. 
3. Kondo M, Wagers AJ, Manz MG, et al. Biology of hematopoietic stem cells and 
progenitors: implications for clinical application. Annu Rev Immunol. 2003;21:759-806. 
4. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a 
single bone marrow-derived stem cell. Cell. 2001;105(3):369-377. 
5. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse 
hematopoietic stem cells. Science. 1988;241(4861):58-62. 
6. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic 
reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 
1996;273(5272):242-245. 
7. MC P, Z. W. Current use and outcome of hematopoietic stem cell transplantation: 
CIBMTR Summary Slides: CIBMTR; 2012. 
8. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 
Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692-698. 
9. Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for 
recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010;363(7):629-639. 
10. Walasek MA, van Os R, de Haan G. Hematopoietic stem cell expansion: challenges and 
opportunities. Ann N Y Acad Sci. 2012;1266:138-150. 
11. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell 
transplantation: marrow or umbilical cord blood? Blood. 2003;101(11):4233-4244. 
12. North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate 
haematopoietic stem cell homeostasis. Nature. 2007;447(7147):1007-1011. 
13. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the 
expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345-1348. 
14. Slukvin II. Hematopoietic specification from human pluripotent stem cells: current 
advances and challenges toward de novo generation of hematopoietic stem cells. Blood. 2013. 
15. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from 
human blastocysts. Science. 1998;282(5391):1145-1147. 
16. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult 
human fibroblasts by defined factors. Cell. 2007;131(5):861-872. 
17. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. 
18. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from 
human somatic cells. Science. 2007;318(5858):1917-1920. 
19. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency 
with defined factors. Nature. 2008;451(7175):141-146. 
20. Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA. Hematopoietic colony-
forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A. 
2001;98(19):10716-10721. 
21. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant 
populations: lessons from embryonic development. Cell. 2008;132(4):661-680. 
116 
 
22. Kennedy M, D'Souza SL, Lynch-Kattman M, Schwantz S, Keller G. Development of the 
hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. 
Blood. 2007;109(7):2679-2687. 
23. Sabin F. Studies on the origin of blood vessels and of red blood corpuscles as seen in the 
living blastoderm of chicks during the second day of incubation. . Contrib Embryol  
1920;272(9):214. 
24. Murray P. The development in vitro of the blood of the early chick embryo. Proc Royal 
Soc London. 1932(11):497-521. 
25. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for 
hematopoietic and endothelial cells. Development. 1998;125(4):725-732. 
26. Fehling HJ, Lacaud G, Kubo A, et al. Tracking mesoderm induction and its specification to 
the hemangioblast during embryonic stem cell differentiation. Development. 
2003;130(17):4217-4227. 
27. Huber TL, Kouskoff V, Fehling HJ, Palis J, Keller G. Haemangioblast commitment is 
initiated in the primitive streak of the mouse embryo. Nature. 2004;432(7017):625-630. 
28. Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and 
definitive haematopoiesis. Nature. 1997;386(6624):488-493. 
29. Ferkowicz MJ, Yoder MC. Blood island formation: longstanding observations and 
modern interpretations. Exp Hematol. 2005;33(9):1041-1047. 
30. Kinder SJ, Tsang TE, Quinlan GA, Hadjantonakis AK, Nagy A, Tam PP. The orderly 
allocation of mesodermal cells to the extraembryonic structures and the anteroposterior axis 
during gastrulation of the mouse embryo. Development. 1999;126(21):4691-4701. 
31. Ueno H, Weissman IL. Clonal analysis of mouse development reveals a polyclonal origin 
for yolk sac blood islands. Dev Cell. 2006;11(4):519-533. 
32. Moore MA, Metcalf D. Ontogeny of the haemopoietic system: yolk sac origin of in vivo 
and in vitro colony forming cells in the developing mouse embryo. Br J Haematol. 
1970;18(3):279-296. 
33. Weismann I, Papaioannou, V. & Gardner, R. . Differentiation of Normal and Neoplastic 
Hematopoietic Cells. New York: Cold Spring Harbor Laboratory Press; 1978. 
34. Dieterlen-Lievre F. On the origin of haemopoietic stem cells in the avian embryo: an 
experimental approach. J Embryol Exp Morphol. 1975;33(3):607-619. 
35. Turpen JB, Knudson CM, Hoefen PS. The early ontogeny of hematopoietic cells studied 
by grafting cytogenetically labeled tissue anlagen: localization of a prospective stem cell 
compartment. Dev Biol. 1981;85(1):99-112. 
36. Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM 
region. Cell. 1996;86(6):897-906. 
37. Müller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E. Development of 
hematopoietic stem cell activity in the mouse embryo. Immunity. 1994;1(4):291-301. 
38. de Bruijn MF, Speck NA, Peeters MC, Dzierzak E. Definitive hematopoietic stem cells first 
develop within the major arterial regions of the mouse embryo. EMBO J. 2000;19(11):2465-
2474. 
39. Kumaravelu P, Hook L, Morrison AM, et al. Quantitative developmental anatomy of 
definitive haematopoietic stem cells/long-term repopulating units (HSC/RUs): role of the aorta-
gonad-mesonephros (AGM) region and the yolk sac in colonisation of the mouse embryonic 
liver. Development. 2002;129(21):4891-4899. 
40. Jaffredo T, Bollerot K, Sugiyama D, Gautier R, Drevon C. Tracing the hemangioblast 
during embryogenesis: developmental relationships between endothelial and hematopoietic 
cells. Int J Dev Biol. 2005;49(2-3):269-277. 
117 
 
41. de Bruijn MF, Ma X, Robin C, Ottersbach K, Sanchez MJ, Dzierzak E. Hematopoietic stem 
cells localize to the endothelial cell layer in the midgestation mouse aorta. Immunity. 
2002;16(5):673-683. 
42. Zovein AC, Hofmann JJ, Lynch M, et al. Fate tracing reveals the endothelial origin of 
hematopoietic stem cells. Cell Stem Cell. 2008;3(6):625-636. 
43. Eilken HM, Nishikawa S, Schroeder T. Continuous single-cell imaging of blood generation 
from haemogenic endothelium. Nature. 2009;457(7231):896-900. 
44. Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C. In vivo 
imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature. 
2010;464(7285):116-120. 
45. Kissa K, Herbomel P. Blood stem cells emerge from aortic endothelium by a novel type 
of cell transition. Nature. 2010;464(7285):112-115. 
46. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The 
haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. 
Nature. 2009;457(7231):892-895. 
47. Rybtsov S, Sobiesiak M, Taoudi S, et al. Hierarchical organization and early 
hematopoietic specification of the developing HSC lineage in the AGM region. J Exp Med. 
2011;208(6):1305-1315. 
48. Miura Y, Wilt FH. Tissue interaction and the formation of the first erythroblasts of the 
chick embryo. Dev Biol. 1969;19(2):201-211. 
49. Pardanaud L, Dieterlen-Lievre F. Emergence of endothelial and hemopoietic cells in the 
avian embryo. Anat Embryol (Berl). 1993;187(2):107-114. 
50. Wilt FH. Erythropoiesis in the Chick Embryo: the Role of Endoderm. Science. 
1965;147:1588-1590. 
51. Belaoussoff M, Farrington SM, Baron MH. Hematopoietic induction and respecification 
of A-P identity by visceral endoderm signaling in the mouse embryo. Development. 
1998;125(24):5009-5018. 
52. Pardanaud L, Dieterlen-Lièvre F. Manipulation of the angiopoietic/hemangiopoietic 
commitment in the avian embryo. Development. 1999;126(4):617-627. 
53. Gering M, Patient R. Hedgehog signaling is required for adult blood stem cell formation 
in zebrafish embryos. Dev Cell. 2005;8(3):389-400. 
54. Byrd N, Becker S, Maye P, et al. Hedgehog is required for murine yolk sac angiogenesis. 
Development. 2002;129(2):361-372. 
55. Dyer MA, Farrington SM, Mohn D, Munday JR, Baron MH. Indian hedgehog activates 
hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the 
mouse embryo. Development. 2001;128(10):1717-1730. 
56. Kumano K, Chiba S, Kunisato A, et al. Notch1 but not Notch2 is essential for generating 
hematopoietic stem cells from endothelial cells. Immunity. 2003;18(5):699-711. 
57. Cheng X, Huber TL, Chen VC, Gadue P, Keller GM. Numb mediates the interaction 
between Wnt and Notch to modulate primitive erythropoietic specification from the 
hemangioblast. Development. 2008;135(20):3447-3458. 
58. Winnier G, Blessing M, Labosky PA, Hogan BL. Bone morphogenetic protein-4 is required 
for mesoderm formation and patterning in the mouse. Genes Dev. 1995;9(17):2105-2116. 
59. Lindsley RC, Gill JG, Kyba M, Murphy TL, Murphy KM. Canonical Wnt signaling is required 
for development of embryonic stem cell-derived mesoderm. Development. 2006;133(19):3787-
3796. 
60. Nottingham WT, Jarratt A, Burgess M, et al. Runx1-mediated hematopoietic stem-cell 
emergence is controlled by a Gata/Ets/SCL-regulated enhancer. Blood. 2007;110(13):4188-4197. 
118 
 
61. Landry JR, Kinston S, Knezevic K, et al. Runx genes are direct targets of Scl/Tal1 in the 
yolk sac and fetal liver. Blood. 2008;111(6):3005-3014. 
62. Lengerke C, Schmitt S, Bowman TV, et al. BMP and Wnt specify hematopoietic fate by 
activation of the Cdx-Hox pathway. Cell Stem Cell. 2008;2(1):72-82. 
63. Paik EJ, Mahony S, White RM, et al. A Cdx4-Sall4 Regulatory Module Controls the 
Transition from Mesoderm Formation to Embryonic Hematopoiesis. Stem Cell Reports. 
2013;1(5):425-436. 
64. Fujiwara Y, Chang AN, Williams AM, Orkin SH. Functional overlap of GATA-1 and GATA-2 
in primitive hematopoietic development. Blood. 2004;103(2):583-585. 
65. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia 
oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell. 
1996;86(1):47-57. 
66. Bollerot K, Pouget C, Jaffredo T. The embryonic origins of hematopoietic stem cells: a 
tale of hemangioblast and hemogenic endothelium. Apmis. 2005;113(11-12):790-803. 
67. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic 
cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell. 
1994;78(1):45-57. 
68. Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only transcription factor 
Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci U S A. 
2000;97(1):320-324. 
69. Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired hematopoiesis, 
and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. 
Mol Cell Biol. 2000;20(15):5643-5652. 
70. Yokomizo T, Hasegawa K, Ishitobi H, et al. Runx1 is involved in primitive erythropoiesis 
in the mouse. Blood. 2008;111(8):4075-4080. 
71. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. Runx1 is required for the 
endothelial to haematopoietic cell transition but not thereafter. Nature. 2009;457(7231):887-
891. 
72. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell 
leukaemia oncoprotein tal-1/SCL. Nature. 1995;373(6513):432-434. 
73. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The 
haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. 
Nature. 2009;457(7231):892-895. 
74. Iacovino M, Chong D, Szatmari I, et al. HoxA3 is an apical regulator of haemogenic 
endothelium. Nat Cell Biol. 2011;13(1):72-78. 
75. Clarke RL, Yzaguirre AD, Yashiro-Ohtani Y, et al. The expression of Sox17 identifies and 
regulates haemogenic endothelium. Nat Cell Biol. 2013;15(5):502-510. 
76. Pimanda JE, Ottersbach K, Knezevic K, et al. Gata2, Fli1, and Scl form a recursively wired 
gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci U S A. 
2007;104(45):17692-17697. 
77. Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R. The in vitro development of 
blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and 
myocardium. J Embryol Exp Morphol. 1985;87:27-45. 
78. Kyba M, Daley GQ. Hematopoiesis from embryonic stem cells: lessons from and for 
ontogeny. Exp Hematol. 2003;31(11):994-1006. 
79. Lindenbaum MH, Grosveld F. An in vitro globin gene switching model based on 
differentiated embryonic stem cells. Genes Dev. 1990;4(12A):2075-2085. 
119 
 
80. Burkert U, von Rüden T, Wagner EF. Early fetal hematopoietic development from in vitro 
differentiated embryonic stem cells. New Biol. 1991;3(7):698-708. 
81. Potocnik AJ, Kohler H, Eichmann K. Hemato-lymphoid in vivo reconstitution potential of 
subpopulations derived from in vitro differentiated embryonic stem cells. Proc Natl Acad Sci U S 
A. 1997;94(19):10295-10300. 
82. Müller AM, Dzierzak EA. ES cells have only a limited lymphopoietic potential after 
adoptive transfer into mouse recipients. Development. 1993;118(4):1343-1351. 
83. Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from 
embryonic stem cells in culture. Science. 1994;265(5175):1098-1101. 
84. Yoder MC, Hiatt K, Mukherjee P. In vivo repopulating hematopoietic stem cells are 
present in the murine yolk sac at day 9.0 postcoitus. Proc Natl Acad Sci U S A. 1997;94(13):6776-
6780. 
85. Perlingeiro RC, Kyba M, Daley GQ. Clonal analysis of differentiating embryonic stem cells 
reveals a hematopoietic progenitor with primitive erythroid and adult lymphoid-myeloid 
potential. Development. 2001;128(22):4597-4604. 
86. Ran D, Shia WJ, Lo MC, et al. RUNX1a enhances hematopoietic lineage commitment 
from human embryonic stem cells and inducible pluripotent stem cells. Blood. 
2013;121(15):2882-2890. 
87. Kyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoid-myeloid 
engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell. 
2002;109(1):29-37. 
88. Rideout WM, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R. Correction of a genetic 
defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002;109(1):17-27. 
89. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model 
with iPS cells generated from autologous skin. Science. 2007;318(5858):1920-1923. 
90. Pelton TA, Sharma S, Schulz TC, Rathjen J, Rathjen PD. Transient pluripotent cell 
populations during primitive ectoderm formation: correlation of in vivo and in vitro pluripotent 
cell development. J Cell Sci. 2002;115(Pt 2):329-339. 
91. Pearson S, Sroczynska P, Lacaud G, Kouskoff V. The stepwise specification of embryonic 
stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and 
VEGF. Development. 2008;135(8):1525-1535. 
92. Irion S, Clarke RL, Luche H, et al. Temporal specification of blood progenitors from 
mouse embryonic stem cells and induced pluripotent stem cells. Development. 
2010;137(17):2829-2839. 
93. Fan R, Bonde S, Gao P, et al. Dynamic HoxB4-regulatory network during embryonic stem 
cell differentiation to hematopoietic cells. Blood. 2012;119(19):e139-147. 
94. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 
1997;278(5340):1059-1064. 
95. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the 
Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks 
definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93(8):3444-3449. 
96. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. Runx1 is required for the 
endothelial to haematopoietic cell transition but not thereafter. Nature. 2009;457(7231):887-
891. 
97. Lichtinger M, Ingram R, Hannah R, et al. RUNX1 reshapes the epigenetic landscape at 
the onset of haematopoiesis. EMBO J. 2012;31(22):4318-4333. 
98. Nottingham WT, Jarratt A, Burgess M, et al. Runx1-mediated hematopoietic stem-cell 
emergence is controlled by a Gata/Ets/SCL-regulated enhancer. Blood. 2007;110(13):4188-4197. 
120 
 
99. Bee T, Ashley EL, Bickley SR, et al. The mouse Runx1 +23 hematopoietic stem cell 
enhancer confers hematopoietic specificity to both Runx1 promoters. Blood. 
2009;113(21):5121-5124. 
100. Ghozi MC, Bernstein Y, Negreanu V, Levanon D, Groner Y. Expression of the human 
acute myeloid leukemia gene AML1 is regulated by two promoter regions. Proc Natl Acad Sci U S 
A. 1996;93(5):1935-1940. 
101. Bee T, Liddiard K, Swiers G, et al. Alternative Runx1 promoter usage in mouse 
developmental hematopoiesis. Blood Cells Mol Dis. 2009;43(1):35-42. 
102. Bee T, Swiers G, Muroi S, et al. Nonredundant roles for Runx1 alternative promoters 
reflect their activity at discrete stages of developmental hematopoiesis. Blood. 
2010;115(15):3042-3050. 
103. Sroczynska P, Lancrin C, Kouskoff V, Lacaud G. The differential activities of Runx1 
promoters define milestones during embryonic hematopoiesis. Blood. 2009;114(26):5279-5289. 
104. Levanon D, Brenner O, Negreanu V, et al. Spatial and temporal expression pattern of 
Runx3 (Aml2) and Runx1 (Aml1) indicates non-redundant functions during mouse 
embryogenesis. Mech Dev. 2001;109(2):413-417. 
105. Pozner A, Goldenberg D, Negreanu V, et al. Transcription-coupled translation control of 
AML1/RUNX1 is mediated by cap- and internal ribosome entry site-dependent mechanisms. Mol 
Cell Biol. 2000;20(7):2297-2307. 
106. Telfer JC, Rothenberg EV. Expression and function of a stem cell promoter for the 
murine CBFalpha2 gene: distinct roles and regulation in natural killer and T cell development. 
Dev Biol. 2001;229(2):363-382. 
107. Wong WF, Nakazato M, Watanabe T, et al. Over-expression of Runx1 transcription 
factor impairs the development of thymocytes from the double-negative to double-positive 
stages. Immunology. 2010;130(2):243-253. 
108. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of 
multiple chromosomal translocations in human leukemia, is essential for normal fetal liver 
hematopoiesis. Cell. 1996;84(2):321-330. 
109. Cai Z, de Bruijn M, Ma X, et al. Haploinsufficiency of AML1 affects the temporal and 
spatial generation of hematopoietic stem cells in the mouse embryo. Immunity. 2000;13(4):423-
431. 
110. Lacaud G, Gore L, Kennedy M, et al. Runx1 is essential for hematopoietic commitment at 
the hemangioblast stage of development in vitro. Blood. 2002;100(2):458-466. 
111. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev 
Cancer. 2002;2(7):502-513. 
112. Pozner A, Lotem J, Xiao C, et al. Developmentally regulated promoter-switch 
transcriptionally controls Runx1 function during embryonic hematopoiesis. BMC Dev Biol. 
2007;7:84. 
113. Challen GA, Goodell MA. Runx1 isoforms show differential expression patterns during 
hematopoietic development but have similar functional effects in adult hematopoietic stem 
cells. Exp Hematol. 2010;38(5):403-416. 
114. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell 
differentiation. Nat Genet. 2012;44(1):23-31. 
115. Trowbridge JJ, Snow JW, Kim J, Orkin SH. DNA methyltransferase 1 is essential for and 
uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell. 2009;5(4):442-449. 
116. Jaenisch R. DNA methylation and imprinting: why bother? Trends Genet. 
1997;13(8):323-329. 
121 
 
117. Song F, Smith JF, Kimura MT, et al. Association of tissue-specific differentially 
methylated regions (TDMs) with differential gene expression. Proc Natl Acad Sci U S A. 
2005;102(9):3336-3341. 
118. Maunakea AK, Nagarajan RP, Bilenky M, et al. Conserved role of intragenic DNA 
methylation in regulating alternative promoters. Nature. 2010;466(7303):253-257. 
119. Iacovino M, Hernandez C, Xu Z, Bajwa G, Prather M, Kyba M. A conserved role for Hox 
paralog group 4 in regulation of hematopoietic progenitors. Stem Cells Dev. 2009;18(5):783-792. 
120. Morgan K, Kharas M, Dzierzak E, Gilliland DG. Isolation of early hematopoietic stem cells 
from murine yolk sac and AGM. J Vis Exp. 2008(16). 
121. Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL. The purification and 
characterization of fetal liver hematopoietic stem cells. Proc Natl Acad Sci U S A. 
1995;92(22):10302-10306. 
122. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human 
embryonic stem cells. Cell. 2005;122(6):947-956. 
123. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses 
identify sites of differential DNA methylation in normal and transformed human cells. Nat 
Genet. 2005;37(8):853-862. 
124. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and 
evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 
2007;39(4):457-466. 
125. Zambidis ET, Peault B, Park TS, Bunz F, Civin CI. Hematopoietic differentiation of human 
embryonic stem cells progresses through sequential hematoendothelial, primitive, and 
definitive stages resembling human yolk sac development. Blood. 2005;106(3):860-870. 
126. Consortium EP. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS 
Biol. 2011;9(4):e1001046. 
127. Ferkowicz MJ, Starr M, Xie X, et al. CD41 expression defines the onset of primitive and 
definitive hematopoiesis in the murine embryo. Development. 2003;130(18):4393-4403. 
128. Hoivik EA, Bjanesoy TE, Mai O, et al. DNA methylation of intronic enhancers directs 
tissue-specific expression of steroidogenic factor 1/adrenal 4 binding protein (SF-1/Ad4BP). 
Endocrinology. 2011;152(5):2100-2112. 
129. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key 
developmental genes in embryonic stem cells. Cell. 2006;125(2):315-326. 
130. Nishida H, Suzuki T, Kondo S, Miura H, Fujimura Y, Hayashizaki Y. Histone H3 acetylated 
at lysine 9 in promoter is associated with low nucleosome density in the vicinity of transcription 
start site in human cell. Chromosome Res. 2006;14(2):203-211. 
131. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are 
essential for de novo methylation and mammalian development. Cell. 1999;99(3):247-257. 
132. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA 
(cytosine-5) methyltransferases. Nat Genet. 1998;19(3):219-220. 
133. Lei H, Oh SP, Okano M, et al. De novo DNA cytosine methyltransferase activities in 
mouse embryonic stem cells. Development. 1996;122(10):3195-3205. 
134. Levanon D, Glusman G, Bangsow T, et al. Architecture and anatomy of the genomic 
locus encoding the human leukemia-associated transcription factor RUNX1/AML1. Gene. 
2001;262(1-2):23-33. 
135. Levanon D, Groner Y. Structure and regulated expression of mammalian RUNX genes. 
Oncogene. 2004;23(24):4211-4219. 
136. Song F, Mahmood S, Ghosh S, et al. Tissue specific differentially methylated regions 
(TDMR): Changes in DNA methylation during development. Genomics. 2009;93(2):130-139. 
122 
 
137. Fujita Y, Nishimura M, Taniwaki M, Abe T, Okuda T. Identification of an alternatively 
spliced form of the mouse AML1/RUNX1 gene transcript AML1c and its expression in early 
hematopoietic development. Biochem Biophys Res Commun. 2001;281(5):1248-1255. 
138. Lorincz MC, Dickerson DR, Schmitt M, Groudine M. Intragenic DNA methylation alters 
chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol. 
2004;11(11):1068-1075. 
139. Szabo E, Rampalli S, Risueño RM, et al. Direct conversion of human fibroblasts to 
multilineage blood progenitors. Nature. 2010;468(7323):521-526. 
140. Deng J, Shoemaker R, Xie B, et al. Targeted bisulfite sequencing reveals changes in DNA 
methylation associated with nuclear reprogramming. Nat Biotechnol. 2009;27(4):353-360. 
141. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of 
pluripotent and differentiated cells. Nature. 2008;454(7205):766-770. 
142. Thillainadesan G, Chitilian JM, Isovic M, et al. TGF-β-dependent active demethylation 
and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex. 
Mol Cell. 2012;46(5):636-649. 
143. Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene 
enhances transcription by an active process. Nat Immunol. 2003;4(3):235-240. 
144. Nagae G, Isagawa T, Shiraki N, et al. Tissue-specific demethylation in CpG-poor 
promoters during cellular differentiation. Hum Mol Genet. 2011;20(14):2710-2721. 
145. North T, Gu TL, Stacy T, et al. Cbfa2 is required for the formation of intra-aortic 
hematopoietic clusters. Development. 1999;126(11):2563-2575. 
146. Telfer JC, Rothenberg EV. Expression and Function of a Stem Cell Promoter for the 
Murine CBFα2 Gene: Distinct Roles and Regulation in Natural Killer and T Cell Development. 
Developmental Biology. 2001;229(2):363-382. 
147. Pimanda JE, Donaldson IJ, de Bruijn MF, et al. The SCL transcriptional network and BMP 
signaling pathway interact to regulate RUNX1 activity. Proc Natl Acad Sci U S A. 2007;104(3):840-
845. 
148. Sun W, Downing JR. Haploinsufficiency of AML1 results in a decrease in the number of 
LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood. 
2004;104(12):3565-3572. 
149. Lacaud G, Kouskoff V, Trumble A, Schwantz S, Keller G. Haploinsufficiency of Runx1 
results in the acceleration of mesodermal development and hemangioblast specification upon in 
vitro differentiation of ES cells. Blood. 2004;103(3):886-889. 
150. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, Smith HO. Enzymatic assembly 
of DNA molecules up to several hundred kilobases. Nat Methods. 2009;6(5):343-345. 
151. Oostendorp RA, Medvinsky AJ, Kusadasi N, et al. Embryonal subregion-derived stromal 
cell lines from novel temperature-sensitive SV40 T antigen transgenic mice support 
hematopoiesis. J Cell Sci. 2002;115(Pt 10):2099-2108. 
152. Wilkinson AC, Goode DK, Cheng YH, et al. Single site-specific integration targeting 
coupled with embryonic stem cell differentiation provides a high-throughput alternative to in 
vivo enhancer analyses. Biol Open. 2013;2(11):1229-1238. 
153. Evans V, Hatzopoulos A, Aird WC, Rayburn HB, Rosenberg RD, Kuivenhoven JA. Targeting 
the Hprt locus in mice reveals differential regulation of Tie2 gene expression in the endothelium. 
Physiol Genomics. 2000;2(2):67-75. 
154. Minami T, Donovan DJ, Tsai JC, Rosenberg RD, Aird WC. Differential regulation of the 
von Willebrand factor and Flt-1 promoters in the endothelium of hypoxanthine 
phosphoribosyltransferase-targeted mice. Blood. 2002;100(12):4019-4025. 
123 
 
155. Dang SM, Kyba M, Perlingeiro R, Daley GQ, Zandstra PW. Efficiency of embryoid body 
formation and hematopoietic development from embryonic stem cells in different culture 
systems. Biotechnol Bioeng. 2002;78(4):442-453. 
156. North TE, de Bruijn MF, Stacy T, et al. Runx1 expression marks long-term repopulating 
hematopoietic stem cells in the midgestation mouse embryo. Immunity. 2002;16(5):661-672. 
157. McKinney-Freeman SL, Naveiras O, Yates F, et al. Surface antigen phenotypes of 
hematopoietic stem cells from embryos and murine embryonic stem cells. Blood. 
2009;114(2):268-278. 
158. Fitch SR, Kimber GM, Wilson NK, et al. Signaling from the sympathetic nervous system 
regulates hematopoietic stem cell emergence during embryogenesis. Cell Stem Cell. 
2012;11(4):554-566. 
159. Yokomizo T, Takahashi S, Mochizuki N, et al. Characterization of GATA-1(+) 
hemangioblastic cells in the mouse embryo. EMBO J. 2007;26(1):184-196. 
160. Ledran MH, Krassowska A, Armstrong L, et al. Efficient hematopoietic differentiation of 
human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell. 
2008;3(1):85-98. 
161. Robin C, Ottersbach K, Durand C, et al. An unexpected role for IL-3 in the embryonic 
development of hematopoietic stem cells. Dev Cell. 2006;11(2):171-180. 
162. Dahl L, Richter K, Hägglund AC, Carlsson L. Lhx2 expression promotes self-renewal of a 
distinct multipotential hematopoietic progenitor cell in embryonic stem cell-derived embryoid 
bodies. PLoS One. 2008;3(4):e2025. 
163. Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, Zúñiga-Pflücker JC. Induction 
of T cell development and establishment of T cell competence from embryonic stem cells 
differentiated in vitro. Nat Immunol. 2004;5(4):410-417. 
164. Burns CE, Traver D, Mayhall E, Shepard JL, Zon LI. Hematopoietic stem cell fate is 
established by the Notch-Runx pathway. Genes Dev. 2005;19(19):2331-2342. 
165. Iacovino M, Bosnakovski D, Fey H, et al. Inducible cassette exchange: a rapid and 
efficient system enabling conditional gene expression in embryonic stem and primary cells. Stem 
Cells. 2011;29(10):1580-1588. 
166. Christian M, Cermak T, Doyle EL, et al. Targeting DNA double-strand breaks with TAL 
effector nucleases. Genetics. 2010;186(2):757-761. 
167. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. 
Science. 2013;339(6121):823-826. 
168. Wong WF, Looi CY, Kon S, et al. T-cell receptor signaling induces proximal Runx1 
transactivation via a calcineurin-NFAT pathway. Eur J Immunol. 2013. 
169. Mukai K, BenBarak MJ, Tachibana M, et al. Critical role of P1-Runx1 in mouse basophil 
development. Blood. 2012;120(1):76-85. 
170. Maguire CA, van der Mijn JC, Degeling MH, Morse D, Tannous BA. Codon-optimized 
Luciola italica luciferase variants for mammalian gene expression in culture and in vivo. Mol 
Imaging. 2012;11(1):13-21. 
171. Osborn MJ, Panoskaltsis-Mortari A, McElmurry RT, et al. A picornaviral 2A-like 
sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled 
to a dual-reporter system. Mol Ther. 2005;12(3):569-574. 
 
 
